Skip to main content
PLOS One logoLink to PLOS One
. 2026 Jun 22;21(6):e0351953. doi: 10.1371/journal.pone.0351953

GL-Net: A knowledge-guided Gaussian-gated and layered refinement network for 3D MRI segmentation of brain gliomas

Huimin Lu 1,2,*, Yilong Wang 1,3, Han Xue 3, Guizeng Wang 2, Jamshid Moradi Kurdestany 4, Songzhe Ma 1,2
Editor: Taikyeong Ted Jeong5
PMCID: PMC13286167  PMID: 42329889

Abstract

Glioblastoma is a highly malignant brain tumor, and accurate lesion segmentation in MRI is essential for diagnosis, treatment planning, and prognosis assessment. This paper proposes a knowledge-guided 3D hybrid Transformer-CNN framework, GL-Net, which integrates prior knowledge through a Gaussian Gating Module (GGM) and a Layered Refinement Module (LRM), together with a novel Edge-Region Voxel Dynamic Weighted Loss Function. These modules collaboratively enhance feature activation, refine label-specific structures, and improve edge delineation, enabling robust segmentation even under limited-sample conditions. The proposed GL-Net was evaluated on the BraTS2019 and BraTS2021 datasets, achieving average Dice Similarity Coefficients (DSC) of 0.877 and 0.913, and Hausdorff Distances (HD) of 1.83 and 1.55, respectively—demonstrating highly competitive performance and a substantial reduction in boundary errors relative to the reported benchmarks of current data-driven approaches. Furthermore, to assess its clinical applicability, VASARI (Visually Accessible Rembrandt Images) feature extraction was performed using both the GL-Net-generated segmentation masks and the ground truth labels on the BraTS2019 dataset for glioblastoma (GBM) diagnosis. The diagnostic performances were nearly identical (GT AUC: 0.954 / GL-Net AUC: 0.949), and the DeLong test (p = 0.99) indicated no statistically significant difference between the two. These results suggest that GL-Net not only achieves highly competitive segmentation accuracy but also produces radiomic features comparable to expert manual annotations, providing complementary evidence of its potential clinical relevance. The proposed framework shows strong clinical potential for precise and consistent glioma delineation, providing valuable support for surgical planning, radiotherapy targeting, and diagnostic decision-making in clinical workflows.

Introduction

Glioblastoma is a complex and severe neurological disease that profoundly affects patients’ lives and overall quality of life. In clinical practice, the characterization and treatment planning of gliomas largely rely on radiological interpretation based on standardized assessment systems. The VASARI (Visually Accessible Rembrandt Images) feature set [1,2] provides a structured vocabulary for describing glioma morphology, including enhancement patterns, necrosis, edema, and mass effect. Although these frameworks offer important guidance for clinical decision-making, they still depend heavily on expert visual assessment and manual delineation, which are time-consuming and subject to considerable inter-observer variability. With the rapid development of deep learning, medical imaging analysis has entered a new era [3]. Among these, CNN and Transformer architectures have gained considerable attention due to their exceptional feature-learning capabilities and ability to model complex relationships [4]. These models can learn from large volumes of medical imaging data, automatically extract features relevant to glioblastoma, and subsequently perform downstream computations [5,6], offering new perspectives for glioblastoma segmentation.

However, in practical semantic segmentation applications, the high heterogeneity and complexity of glioblastoma pose significant challenges. Models that rely solely on data-driven approaches often fail to achieve optimal performance, particularly in the following aspects: (1) The imaging characteristics of glioblastoma are highly diverse, with complex morphological and signal intensity variations on MRI. These factors make it difficult for algorithms based solely on image feature recognition to perform accurately; (2) Due to the relatively limited number of available cases, i.e., the small sample problem, training datasets are often insufficient to capture all potential patterns of disease variation. This frequently leads to overfitting and poor generalization in models [7], reducing accuracy in real-world predictions, especially when dealing with blurred tumor boundaries or overlapping regions.

To address these challenges, incorporating prior knowledge is critically important [8]. Prior knowledge may include information about the morphology and biological characteristics of glioblastoma, as well as domain expertise in the medical field [9]. By integrating such knowledge into deep learning models to enhance their regulatory constraints, the models can better understand the characteristics of glioblastoma, thereby improving the accuracy and robustness of segmentation results.

This study aims to develop a small-sample glioblastoma segmentation algorithm that seamlessly integrates deep learning with prior knowledge. To achieve this, the innovative GL-Net was designed. Through this algorithm, GL-Net enables more efficient recognition and segmentation of glioblastoma, providing more precise and reliable support for clinical diagnosis and treatment. Furthermore, we applied the model-generated segmentation results to the VASARI framework for GBM characterization and compared them with the gold-standard segmentations. This comparison highlights the potential clinical relevance and translational value of the proposed model. The main innovations of this study are as follows:

  • (1) GL-Net: By combining data-driven and knowledge-driven approaches, an innovative framework based on a hybrid structure of Transformer and CNN was designed. Prior knowledge is integrated into the model through the Gaussian Gating Module (GGM), Layered Refinement Module (LRM), and Edge-Region Voxel Dynamic Weighted Loss Function. This effectively leverages prior knowledge to enhance the overall performance of the model.

  • (2) Gaussian Gating Module: A secondary feature optimization module based on Gaussian functions was designed to effectively activate secondary features while suppressing overly sensitive or insensitive features. By leveraging the modulation capabilities of Gaussian functions, the module enhances the neural network’s ability to identify under-activated regions, such as the blurred edge areas of glioblastoma.

  • (3) Layered Refinement Module: A Layered Refinement Module based on label priors is proposed to progressively refine the prediction results for different label types, identifying and correcting mispredictions. This module employs a detail-aware extractor (DAE) that utilizes deep supervision and multi-scale feature fusion to extract and refine detailed features, thereby improving segmentation accuracy.

  • (4) Edge-Region Voxel Dynamic Weighted Loss Function: A novel loss function, DiceBRD loss, is introduced to focus more on the voxels in edge regions. Through a dynamic weighting mechanism, it alleviates the class imbalance problem. By adaptively adjusting the penalty for misclassified voxels in edge regions, this loss function enhances model accuracy in medical image segmentation tasks.

  • (5) The VASARI framework: The proposed GL-Net model is applied to the VASARI framework for GBM characterization, which is a comprehensive and reliable method for evaluating GBM. By comparing the model-generated segmentation results with the gold-standard segmentations, the potential clinical relevance of the proposed model is demonstrated.

The remaining sections of this paper are organized as follows: In the Related Work section, we introduce relevant studies on semantic segmentation algorithms that are purely data-driven. The Methods section details the experimental methods used in this study, including the overall framework of the model, the workflow, and the design details of the proposed innovative modules. The Experiment and Analysis section presents the main evaluation metrics, the datasets used, detailed experimental procedures, and a comparative analysis of the results.

Related work

The encoder-decoder structure of CNN models like U-Net

In previous studies, convolutional neural network (CNN)-based architectures have dominated the field of data-driven medical image semantic segmentation tasks, with models like U-Net [10], which adopt an encoder-decoder structure, has demonstrated particularly strong performance. The U-Net model achieves semantic segmentation of medical images through a symmetric encoder and decoder structure. The encoder extracts deep semantic features, progressively downsampling to capture global contextual information, while the decoder progressively upsampling to restore image resolution and reconstruct spatial details. Skip connections transfer high-resolution features between the encoder and decoder, ensuring that local details are preserved and improving the precision of edge segmentation. This model is particularly well-suited for small-sample medical image datasets, as it can capture global information while retaining local details.

In recent years, researchers have continuously improved and extended U-Net to address the challenges in the field of glioma segmentation. Some researchers have focused on introducing attention mechanisms to enhance segmentation performance by capturing significant regions. For example, Xu et al. [11] designed a novel U-Net by incorporating a corner attention module, which efficiently extracts dimensional information between slices and strengthens contextual connections, thus enhancing the network’s representational capacity. Schlemper et al. [12] proposed an Attention Gate (AG) model for medical image analysis, which highlights salient features useful for specific tasks. Akbar et al. [13] introduced a multi-path residual attention module based on the U-Net architecture, adding an attention gating mechanism in the skip connections to increase the model’s focus on target regions and reduce attention to non-target regions. Jia et al. [14] proposed an end-to-end glioma segmentation algorithm based on 3D U-Net, incorporating a coordinate attention module to enhance the ability to capture local texture features and global positional information. These improvements have significantly improved the network’s ability to accurately identify and segment regions of interest in glioma processing, providing strong support for glioma analysis.

Transformer and its combined model with CNN

The Transformer [15] is a model architecture based on the Multi-Head Attention (MHA) mechanism. Through parallel processing and self-attention mechanisms, it can more effectively capture long-range dependencies in sequences. As a result, researchers have started using Transformer to explore its potential in extracting information across different modalities for glioma segmentation.

For example, Lin et al. [16] grouped input modalities into two categories based on MRI imaging principles and named the model CKD-TransBTS. This model leverages the Transformer’s advantages, capturing local lesion boundaries and extracting long-range features from 3D images. Hu et al. [17] proposed an efficient R-Transformer dual-encoder network, which captures complex semantic features and global contextual information by constructing a feature branch and a patch branch. Li et al. [18] introduced a new DenseTrans network that utilizes the shifted window operation of the Swin Transformer to obtain global feature information and long-range dependency modeling capabilities. Yang et al. [19] proposed a flexible multimodal glioma segmentation fusion network, which employs two Transformer-based feature learning networks and a cross-modal shared learning network to extract both individual and shared feature vectors, improving glioma segmentation performance using multimodal images. Ting et al. [20] introduced a multimodal Transformer to model correlations between multimodal features, progressively integrating multimodal and multilevel features for glioma segmentation using spatial and channel self-attention modules.

The aforementioned algorithms fully integrate the Transformer’s ability to capture global contextual information without being constrained by the receptive field, enabling better feature and structural information extraction in glioma image segmentation tasks. By employing methods such as the cross-fusion of global and local features, improvements to skip connection structures, and the integration of multimodal information, the accuracy and generalization capability of segmentation algorithms can be enhanced. While the self-attention mechanism in the Transformer captures global information well, it is less effective in handling local details. In images, pixels in local regions often exhibit strong correlations, and when processing images, the Transformer may not effectively capture this local correlation, leading to insufficient utilization of information.

Consequently, some researchers have developed hybrid architectures that integrate CNNs and Transformers. For example, Wang et al. [21] were the first to propose a novel glioma segmentation model called TransBTS, which combines CNNs and Transformers to extract spatial features and capture long-range dependencies. Liang et al. [22] proposed a TransConver model based on CNNs and Transformers, achieving cross-fusion of global and local features while improving skip connection structures to mitigate the semantic gap between encoder and decoder features for better fusion. Zhu et al. [23] introduced a glioma segmentation algorithm that utilizes multimodal MRI data and integrates semantic and edge information through deep learning techniques, aiming to fully leverage multimodal information.

In handling glioma segmentation tasks, these algorithms combine the advantages of classic deep learning models like CNNs, resulting in models with improved feature extraction and spatial information processing capabilities. By incorporating traditional algorithms, these models achieve a more comprehensive analysis and interpretation of medical images. However, the performance of CNN-Transformer architectures often relies on large amounts of annotated data. In the field of medical imaging, obtaining large quantities of annotated data can be challenging. Nevertheless, algorithms that incorporate prior knowledge can effectively address this issue. By leveraging the expertise and experience of medical professionals, models can be guided during training to better understand and analyze images, thus improving segmentation accuracy.

Loss functions and the issue of class imbalance

In medical image analysis, tumor regions are significantly smaller than normal regions. Even within a single brain slice, the tumor area is much smaller than other parts of the brain, leading to class imbalance in medical images [24]. To effectively address this issue, researchers have worked on improving loss functions. Lin et al. [25] first proposed the focal loss for object detection in image segmentation, which introduces a modulation factor to alleviate the class imbalance problem. Caliva et al. [26] used a distance map as the weight for cross-entropy, allowing the loss to focus on difficult-to-segment boundary regions. Kervadec et al. [27] developed an edge loss algorithm that calculates region interfaces by integrating along boundaries, formulating it as a distance metric in contour space. Karimi et al. [28] introduced a loss function based on the Hausdorff Distance (HD) to directly minimize the HD between the model-generated contours and the ground truth. Liu et al. [24] proposed a multi-level structural loss by utilizing region, boundary, and pixel information to supervise feature fusion and achieve precise segmentation. Yeung et al. [29] proposed a Unified Focal Loss to address the issues of excessive hyperparameters and overly fast convergence in general focal loss. Du et al. [30] developed a boundary-sensitive loss function that automatically focuses on hard-to-segment boundaries, leading to more refined target delineation.

Although these algorithms help mitigate class imbalance to some extent, they still have limitations. For example, some algorithms rely on manually tuned hyperparameters or complex computational processes, increasing the difficulty of optimization. Additionally, certain methods do not sufficiently emphasize boundary regions, which can limit segmentation precision.

Materials and methods

Materials

The glioma MRI data used in this study were obtained from the standardized multi-center TCGA and TCIA repositories [33–35]. The BraTS2019 training set includes 259 high-grade glioma (HGG) and 76 low-grade glioma (LGG) cases, while the BraTS2021 dataset comprises 1,251 cases in total. The scans were collected from 13 independent medical institutions using MRI systems from GE, Siemens, and Philips, covering a magnetic field strength range of 0.5 T-3 T and incorporating diverse acquisition protocols (slice thickness: 1–3 mm, TR: 500–3000 ms, TE: 10–100 ms, matrix size: 128×128–512×512). This inherent clinical and technical heterogeneity enables GL-Net to learn tumor representations that are independent of specific scanners and acquisition protocols, thereby supporting its robust generalization under real-world imaging conditions.

Methods

Compared to natural images, extracting feature information from medical images is significantly more challenging, especially in multi-sequence medical imaging. Since optimal tumor image slices cannot always be guaranteed, our overall model strategy is built on 3D data to better adapt to practical applications (Fig 1). In this study, we designed a novel Gaussian-gated and secondary refinement segmentation algorithm, GL-Net, based on T-CNN (as shown in Fig 2). To fully integrate layered feature information from different structures, we introduce a Gaussian-gated module for secondary feature optimization, effectively fusing feature representations from both sides. On the decoder side, we design a label-prior-based LRM, which progressively refines the WT, TC, and ET regions, ultimately achieving accurate segmentation. Additionally, we propose a new region-dynamic-weighted loss function that mitigates the class imbalance problem by adjusting the computation domain and enhancing the decoder’s focus on image edges.

Fig 1. Clinical integration workflow of GL-Net segmentation.

Fig 1

Fig 2. Network architecture of GL-Net.

Fig 2

Gaussian gating module for secondary feature optimization.

To effectively utilize the unique features of T-CNN, it is essential to address the issues of noise in layered features and the compatibility of intrinsic differences. To achieve this goal, this paper introduces a Gaussian Gating Module for secondary feature optimization. The Gaussian function enhances secondary features while suppressing both the most and least sensitive features [31]. In deep learning-based medical image segmentation, secondary features refer to regions that are not fully activated during the neural network’s learning process. As shown in Fig 3, these unactivated regions are primarily distributed along the fuzzy boundary areas of gliomas. To effectively activate secondary features, this paper proposes a Gaussian Gating Module for secondary feature optimization leveraging the modulation properties of Gaussian functions, as illustrated in Fig 4.

Fig 3. Activation mapping of glioma region.

Fig 3

Fig 4. Gaussian gating module for secondary feature optimization.

Fig 4

First, the feature vectors FTransi extracted by MHA and FConvi extracted by the convolution kernel are passed through a 31×13 convolution kernel to reduce the original number of channels to Ci/2, which helps alleviate the computational burden of subsequent operations. To ensure spatial alignment between FTransi and FConvi, FTransi needs to undergo an upsampling operation. Next, the two feature maps are merged through a concatenation operation, followed by average pooling (AvgPool) and max pooling (MaxPool) operations to obtain the feature vectors FTransi and FConvi, respectively. Then, the output is passed through a 31×13 convolutional layer, and the resulting feature map is further processed using a Gaussian function to obtain the normalized weight wi∈[0,1]. This weight reactivates the secondary features of both, compensating for the lost edge features. Finally, FTransi and FConvi are multiplied by the normalized weight wi. The above process can be expressed by Equations (1) to (5):

Fmeani=mean({Up(Conv(FTransi)),Conv(FConvi)}) (1)
Fmaxi=max({Up(Conv(FTransi)),Conv(FConvi)}) (2)
wi=gauss(Conv({Fmeani,Fmaxi})) (3)
FTransi′=wi⊗FTransi (4)
FConvi′=wi⊗FConvi (5)

Next, the activated feature maps are concatenated. To preserve the original information of the feature representations FTransi and FConvi, the activated features are concatenated again with FTransi and FConvi, followed by a convolution operation to generate the feature representation F(i′). The above process can be expressed by Equation (6):

F(i′)=Conv({FTrans(i′),FConv(i′),Up(Conv(FTransi)),Conv(FConvi)}) (6)

In addition, to retain the contextual information from the previous layer in the encoder, the fused feature F(i′) can be combined with the output Fi+1 of the Gaussian Gating Module from the previous layer through a concatenation operation. Finally, the features of both are extracted through a convolutional layer. This process can be expressed by Equation (7):

Fi=Conv({F(i′),Up(Conv(F(i+1)))}) (7)

In the equation, Fi and Fi+1 represent the outputs of the Gaussian Gating Module at the current level and the previous level, respectively.

Layered refinement module based on label priors.

To address the impact of unclear boundaries and overlapping regions, this paper introduces an LRM. Inspired by the labeling format of gliomas, it is designed to progressively refine the prediction results for different types of labels, as shown in Fig 5. The purpose of this module is to identify and correct mispredictions. It takes deep features and current layer features as input and outputs the refined features along with the current layer’s prediction results.

Fig 5. LRM based on label prior.

Fig 5

First, the deep features FLR(i+1)={FWT(i+1),FTC(i+1),FET(i+1)}, FLR(i+1)∈ℝ3×N×C×H×W, and their components FWT(i+1),FTC(i+1),FET(i+1) undergo convolution operations to reduce the number of channels to 1, resulting in the corresponding predicted maps. Second, deep supervision is applied to the generated predicted maps, guiding the detail-aware extraction module to refine the detail features of the corresponding predictions. Finally, upsampling and activation operations are performed sequentially to obtain the corresponding activation values. The specific process is described in Equation (8):

Actj=σ(Up(Conv(FLRj(i+1)))) (8)

In the formula, FLR(i+1) represents the deep features of the (i + 1)-th layer, Actj denotes the activation value for refining the j-th target region, where j takes values from {WT, TC, ET}. σ represents the Sigmoid function.

Secondly, this paper multiplies ActWT∈Actj with the current feature FCi to generate the foreground attention feature for WT. Subsequently, this feature is fed into the DAE to perform the detail extraction task, resulting in the detail feature FCWTi for WT. Then, ActTC is multiplied with FCWTi to obtain the foreground attention feature for TC, and the detail feature FCTCi for TC is extracted using the DAE. Similarly, the detail feature FCETi can be obtained. This process can be expressed by Equation (9).

FCji=DAE(Actj⊙FC(j−1)i) (9)

In the formula, FC(j−1)i represents the detail feature from the previous layer of the DAE for FCji, where j takes values sequentially from {WT, TC, ET}; j denotes the DAE.

Then, this paper first performs convolution and upsampling operations on the deep feature FLR(i+1), and then adds it to the features extracted by the DAE. Secondly, normalization and nonlinear activation are performed through the BR layer on FLR(i−1). This process can be expressed by Equations (10) to (14).

FCji=DAE(Actj⊙FC(j−1)i) (10)
FWT(i−1)=BR(FCWTi+αFfWTi) (11)
FTC(i−1)=BR(FCTCi+βFfTCi) (12)
FET(i−1)=BR(FCETi+γFfETi) (13)
FLR(i−1)={FWT(i−1),FTC(i−1),FET(i−1)} (14)

In the formula, BR(·) denotes the BN + ReLU operation.

Multi-scale feature fusion DAE: The input features are first processed through a 1×1 convolution kernel, reducing the original channel size Ci to Ci/4, which helps reduce the computational burden of subsequent operations. This is followed by a batch normalization layer and a ReLU operation. Four parallel branches are then established to provide various receptive fields for matching candidate regions of different sizes and shapes. In each branch, a 3×3 dilated convolution kernel is used, with a specific dilation rate and padding size. These four branches are then merged to obtain the fused features. Finally, a 1×1 convolution kernel, batch normalization layer, and ReLU operation are applied to fuse the concatenated features, resulting in the detailed feature vector, as shown in Fig 6.

Fig 6. Structure of the detail-aware extractor for multi-scale feature fusion.

Fig 6

Dynamic weighted loss function for edge region voxels.

In medical images, the presence of abundant noise and artifacts often leads to blurred target edge contours, which significantly affects the loss function. To address this issue, this paper introduces an edge-region voxel dynamic weighting loss function, called DiceBRD loss [32], as shown in Fig 7. This loss not only alleviates the class imbalance problem caused by the asymmetry between the number of foreground and background voxels but also precisely identifies the true edges by adaptively adjusting the penalty for misclassified voxels in edge regions. This improves the accuracy of deep neural networks in medical image segmentation.

Fig 7. Flowchart of the dynamic weighted loss function for edge region voxels.

Fig 7

Red, green, and white areas represent the predicted values, ground truth labels, and background, respectively.

DiceBRD loss extracts the edges of both the predicted results and the ground truth labels during the training iterations as the regions for loss calculation. The union of these regions defines the region of interest (ROI) for recalculating the loss. The edge extraction process can be expressed using equations (15) to (17).

Rlogits=ISourceLogits−IErosionLogits (15)
Rtargets=ISourceTargets−IErosionTargets (16)
R=Rlogits∪Rtargets (17)

Here, R represents the dynamically extracted boundary region of interest (ROI). The overall loss function, LDiceBRD, is formulated as a combination of a global Dice loss (LDice) calculated over the entire image volume, and a Boundary Region-restricted Dynamic weighted cross-entropy loss (LBRD) calculated strictly within the dynamic ROI R.

To integrate both global topological structure and local boundary refinement, the proposed LDiceBRD elegantly decouples the learning objectives. The overall loss is formulated as a weighted sum of the global Dice loss (LDice) calculated over the entire image volume, and the Boundary Region-restricted Dynamic weighted cross-entropy loss (LBRD) calculated strictly within the dynamically extracted boundary region.

Specifically, the global LDice is defined as Equation (18):

LDice=1−2∑i∈V∑c=0Cyicpic+ε∑i∈V∑c=0C(yic+pic)+ε (18)

The local boundary-restricted term LBRD is defined as Equation (19):

LBRD=−1|R|∑i∈R∑c=0Cwiyiclog(pic) (19)

Finally, the concise combined loss equation is explicitly formulated as Equation (20):

LDiceBRD=LDice+λLBRD (20)

To ensure absolute clarity, all symbols utilized in the above formulations are consistently defined as follows:

  • V: The set of all voxels in the entire global image volume.

  • R: The dynamically extracted boundary region of interest (R⊆V).

  • |R|: The total number of voxels strictly within the boundary region R.

  • C: The total number of segmentation classes (including the background).

  • yic∈{0,1}: The ground truth one-hot encoding indicating whether voxel i belongs to class c.

  • pic∈[0,1]: The predicted probability that voxel i belongs to class c.

  • wi: The dynamic adaptive weight, computed as the Euclidean distance from voxel i to the exact boundary, heavily penalizing boundary misclassifications.

  • ε: A small smoothing factor added to prevent division by zero.

  • λ: A hyperparameter balancing the contribution of the local boundary refinement against the global structural loss (in our implementation, λ is set to 1.0).

By defining the Dice term over the global domain V, the model effectively mitigates the severe class imbalance inherent in medical images. Conversely, by restricting the weighted cross-entropy term (LBRD) strictly to the dynamically evolving boundary domain R via the balancing weight λ, the model adaptively forces the network to refine blurry contours without overwhelming the loss gradients with easy background voxels.

GBM diagnosis based on VASARI.

In this study, we developed an automated pipeline for extracting VASARI features F4-F7 based on multi-sequence MRI and tumor segmentation masks. First, all MRI sequences were resampled to the spatial coordinate system of the label image to ensure voxel-wise spatial consistency. Tumor subregions—Whole Tumor (WT), tumor core (TC), and Enhancing Tumor (ET)—were defined according to the BraTS specifications. Additionally, connected component analysis was applied to remove small-volume noise and obtain stable tumor masks. The specific extraction rules are as follows:

  • F4 (Enhancement quality): Describes the degree of signal enhancement on post-contrast T1-weighted MRI, categorized as Absent, Minimal, or Avid. This requires comparing signal intensity changes in the tumor region between pre- and post-contrast T1-weighted images.

  • F5 (Enhancing Tumor proportion): The percentage of the tumor composed of enhancing regions.

  • F6 (Non-Enhancing Tumor proportion): The percentage of the tumor composed of non-enhancing regions.

  • F7 (Necrosis proportion): The percentage of the tumor composed of necrotic regions. These extracted features were subsequently used as inputs to a logistic regression classifier for GBM prediction.

Results

Dataset and evaluation metrics

This paper conducts experiments on the BraTS2019 and BraTS2021 [33–35] datasets to validate the effectiveness of the proposed algorithm. The BraTS2019 training set consists of 259 HGG and 76 LGG cases. The BraTS2021 official training dataset consists of 1,251 cases. Since the ground truth labels for the official validation and test sets of BraTS2019 and BraTS2021 are withheld by the challenge organizers and are not publicly available, all models in this study were trained and evaluated exclusively on the official training datasets. To ensure a robust and fair evaluation, a five-fold cross-validation strategy was performed. Therefore, any reference to “test set” or “test results” in this paper specifically denotes the internal hold-out test folds partitioned during this cross-validation process, rather than the official unseen BraTS test sets. The average results of the five runs are reported. In addition, for BraTS2019, we compared GBM predictions based on VASARI features extracted from the GL-Net-generated masks and from the gold-standard masks.

To evaluate the model’s potential clinical relevance, the following evaluation metrics(21–22) will be used:

DSC=2TP2TP+FP+FN (21)
HD(x,y)=max[supx∈Xinfy∈Yd(x,y),supy∈Yinfx∈Xd(x,y)] (22)

In this equation, TP represents the cases where the model correctly predicts the positive class. FP represents the instances where the model incorrectly predicts the negative class as positive. FN refers to the cases where the model incorrectly predicts the positive class as negative. X and Y are two proper subsets of the metric space M, with sup representing the supremum and inf representing the infimum.

For GBM diagnosis based on VASARI, commonly used classification metrics were employed, including ACC (Accuracy), Precision, Sensitivity (Recall), Specificity, F1-score, and AUC (Area Under the Curve).

Furthermore, to rigorously validate the performance improvements of the proposed GL-Net, statistical significance testing was conducted. The quantitative segmentation results across the five-fold cross-validation are reported as Mean ± Standard Deviation (SD). A paired Student’s t-test was utilized to determine whether the performance differences between the baseline configurations (or comparative models) and the proposed GL-Net were statistically significant across the test folds. A p-value of < 0.05 was considered statistically significant, and p < 0.01 was considered highly significant.

Experimental setup and preprocessing

All experiments in this paper use MRI data provided by the BraTS2019 and BraTS2021 datasets. First, padding and cropping are performed to resize the images to 160 × 160 × 160, followed by Z-score normalization, where the mean of the normalized data is 0 and the variance is 1. Then, slice operations are carried out along the axial plane with a channel depth of 1, reducing the image size to 160 × 160. All experiments were conducted on an Ubuntu operating system equipped with an Intel(R) Xeon(R) CPU E5-2678 v3 @ 2.50GHz, 128 GB of system RAM, and dual NVIDIA RTX 3090 Ti GPUs (24 GB VRAM each). The proposed GL-Net has a total parameter count of approximately 35.2 M. Under this hardware configuration, the total training time for 100 epochs was approximately 14 hours, and the average inference time per patient volume during the testing phase was around 4.2 seconds, which fully meets the efficiency requirements for clinical practice.

For the training phase, the input image size is 3×160×160, the batch size is set to 8, and the number of epochs is 100. The optimization method used is SGD, with a weight decay of 0.0001, momentum set to 0.99, and the initial learning rate lr0 set to 1.5 × 10−3. The learning rate changes as the number of training iterations increases, as described by the following equation (22):

lr=lr0×(1−epoch100)0.9 (23)

Our code will be open-sourced at https://github.com/Turing17/GL-Net.

Comparative experiments of GL-Net

First, the proposed GL-Net is evaluated on the internal hold-out test sets partitioned from the BraTS2019 and BraTS2021 official training data, and the results are compared with advanced algorithms, as shown in Tables 1 and 2 (Figs 8 and 9). It is important to note that the quantitative results of the comparative models presented in these tables are directly cited from their respective original publications rather than re-implemented in our exact experimental environment. While this provides a comprehensive contextual benchmark against current state-of-the-art methods, we explicitly acknowledge that these constitute indirect comparisons rather than head-to-head evaluations within a unified framework. Differences in preprocessing methods, training pipelines, and specific cross-validation splits can significantly impact performance metrics. Therefore, these comparative results should be interpreted with caution. Consequently, rather than claiming absolute superiority, we frame our results as highly competitive, noting that a definitive benchmarking would require re-implementing all models under an identical pipeline. In the BraTS2019, GL-Net achieves DSC scores of 0.855, 0.916, and 0.860 for the ET, WT, and TC regions, respectively. Notably, the DSC scores for the ET and WT regions are the highest. Additionally, GL-Net achieves HD values of 1.51 mm, 2.39 mm, and 1.59 mm for the ET, WT, and TC regions, respectively, with these HD values comparing favorably against current segmentation algorithms. Since the boundary between the TC and WT regions is relatively vague in some glioma datasets, GL-Net, compared to reference [23], lacks an edge detection module and thus does not extract edge features effectively. As a result, its performance in the TC region is inferior to that in reference [23], but GL-Net shows significant improvements in the ET and WT regions. Compared to the TransConver model [22], which is based on transformers and CNNs, GL-Net shows favorable results across most segmentation metrics, with particularly good performance in the ET region. In the BraTS2021 internal test set, GL-Net achieves DSC scores of 0.899, 0.936, and 0.905 for the ET, WT, and TC regions, respectively. Furthermore, GL-Net achieves HD values of 1.12 mm, 1.85 mm, and 1.68 mm for the ET, WT, and TC regions, respectively. Compared to the dual-branch network model based on attention mechanisms and super-resolution reconstruction (Jia et al.), GL-Net achieves highly comparable or superior metrics relative to the reported results of this algorithm, particularly in the segmentation of the WT and TC regions. Compared to the DenseTrans model proposed by Li et al. [18], GL-Net achieves excellent segmentation performance in the ET and TC regions, with further improvements in the WT region as well.

Table 1. The comparative experimental results of the GL-Net with other models on the BraTS2019.

Author DSC HD
ET WT TC Avg ET WT TC Avg
Schlemper et al [12] 0.760 0.888 0.772 0.806 5.20 7.76 8.26 7.07
Akbar et al [13] 0.742 0.885 0.810 0.812 6.67 10.25 10.83 9.25
Liang et al [22] 0.789 0.859 0.838 0.828 2.69 2.59 1.61 2.29
Wang et al [21] 0.789 0.900 0.819 0.836 3.74 5.64 6.05 5.14
Rehman et al [36] 0.763 0.884 0.814 0.820 – – – –
Zhu et al [23] 0.838 0.916 0.892 0.882 3.08 3.87 5.12 4.02
Chang et al [37] 0.782 0.890 0.812 0.828 3.82 8.53 7.43 6.59
AboElenein et al [38] 0.808 0.866 0.858 0.844 9.50 11.20 8.01 9.57
GL-Net 0.855 0.916 0.860 0.877 1.51 2.39 1.59 1.83

DSC — Dice Similarity Coefficient; HD — Hausdorff Distance. The performance metrics of the compared models are directly cited from their original publications.

Table 2. The comparative experimental results of the GL-Net with other models on the BraTS2021.

Author DSC HD
ET WT TC Avg ET WT TC Avg
Akbar et al [13] 0.777 0.893 0.822 0.830 30.90 16.09 11.34 19.44
Mazumdar et al [39] 0.812 0.907 0.852 0.857 26.47 5.94 13.83 15.41
Jia et al [14] 0.896 0.911 0.883 0.896 1.41 4.58 7.81 4.60
Lin et al [16] 0.885 0.933 0.902 0.906 5.93 6.20 6.54 6.22
Li et al [18] 0.883 0.932 0.862 0.892 12.20 4.58 14.80 10.52
GL-Net 0.899 0.936 0.905 0.913 1.12 1.85 1.68 1.55

DSC — Dice Similarity Coefficient; HD — Hausdorff Distance. The performance metrics of the compared models are directly cited from their original publications.

Fig 8. Bar chart of the comparison experiment results of GL-Net with other models on the BraTS2019.

Fig 8

Fig 9. Bar chart of the comparison experiment results of GL-Net with other models on the BraTS2021.

Fig 9

In summary, GL-Net performs excellently in both DSC and HD metrics, demonstrating highly competitive segmentation optimization capabilities alongside current mainstream segmentation algorithms. This is due to GL-Net’s effective utilization of secondary features and further extraction through the LRM, which enhances the segmentation performance for brain gliomas. Fig 10 presents a visual comparison of the segmentation results for brain gliomas obtained by different algorithms. By comparing with the Ground Truth (GT), GL-Net achieves more accurate segmentation results than other algorithms, further validating the superior segmentation performance of the proposed algorithm from a qualitative analysis perspective.

Fig 10. Examples of segmentation results on the BraTS2019 for the GL-Net, compared with other algorithms.

Fig 10

WT: green + red + yellow, TC: red + yellow, ET: yellow.

Ablation experiments

Tables 3 and 4 display the quantitative ablation results of GL-Net on the BraTS2019 and BraTS2021 datasets, respectively, reported as Mean ± SD. To ensure absolute statistical rigor and account for potential non-normal distributions in the case-level metric differences, we report p-values from both the paired Student’s t-test and the non-parametric Wilcoxon signed-rank test (presented in parentheses). It can be observed that each of the proposed modules contributes to further improvements in segmentation performance. Crucially, both statistical tests reveal that the full GL-Net architecture (ALL) achieves highly significant improvements (p < 0.01) over the baseline T-CNN across almost all subregions in both DSC and HD metrics. While the individual addition of either the Gaussian Gating Module (GGM) or the Layered Refinement Module (LRM) noticeably enhances the segmentation of brain gliomas, the full model consistently yields statistically superior and more stable results (indicated by smaller standard deviations). This confirms that the performance gains are robust across the patient volumes and not driven by random variance. Fig 11 presents a comparison of the ablation study results for this algorithm. From the figure, it can be observed that, after incorporating the Gaussian Gating Module, inactive regions are effectively activated, enhancing the recognition of blurred edges. Furthermore, after adding the LRM, the segmentation performance of the WT, TC, and ET regions becomes more closely aligned with the ground truth labels.

Table 3. Ablation experiment results of GL-Net on the BraTS2019.

Model Region DSC HD
T-CNN ET 0.827±0.031(p < 0.01,p < 0.01) 3.51±0.55(p < 0.01,p < 0.01)
WT 0.878±0.028(p < 0.01,p < 0.01) 4.88±0.72(p < 0.01,p < 0.01)
TC 0.836±0.030(p < 0.01,p < 0.01) 3.79±0.61(p < 0.01,p < 0.01)
T-CNN + GGM ET 0.845±0.027(p < 0.01,p < 0.01) 2.25±0.42(p < 0.01,p < 0.01)
WT 0.893±0.025(p < 0.01,p < 0.01) 3.15±0.51(p < 0.01,p < 0.01)
TC 0.856±0.028(0.10,0.08) 2.65±0.45(p < 0.01,p < 0.01)
T-CNN + LRM ET 0.850±0.025(0.04,0.06) 2.01±0.38(p < 0.01,p < 0.01)
WT 0.897±0.024(p < 0.01,p < 0.01) 2.95±0.48(p < 0.01,p < 0.01)
TC 0.848±0.026(p < 0.01,p < 0.01) 2.81±0.49(p < 0.01,p < 0.01)
ALL ET 0.855±0.022 1.51±0.30
WT 0.916±0.020 2.39±0.35
TC 0.860±0.024 1.59±0.32

5-fold cross-validation results are presented as Mean ± Standard Deviation (SD). Values in parentheses (pt-test,pwilcoxon) indicate p-values from the paired Student’s t-test and the non-parametric Wilcoxon signed-rank test, respectively, comparing the respective baseline model against the final proposed model (ALL / DiceBRD loss). A value of (p < 0.01) denotes p < 0.01. Extremely small p-values are reported as p < 0.01 following standard statistical reporting guidelines.

Table 4. Ablation experiment results of GL-Net on the BraTS2021.

Model Region DSC HD
T-CNN ET 0.855±0.029(p < 0.01,p < 0.01) 3.58±0.58(p < 0.01,p < 0.01)
WT 0.883±0.027(p < 0.01,p < 0.01) 4.88±0.65(p < 0.01,p < 0.01)
TC 0.869±0.028(p < 0.01,p < 0.01) 4.03±0.62(p < 0.01,p < 0.01)
T-CNN + GGM ET 0.870±0.025(p < 0.01,p < 0.01) 2.45±0.45(p < 0.01,p < 0.01)
WT 0.910±0.023(p < 0.01,p < 0.01) 3.92±0.54(p < 0.01,p < 0.01)
TC 0.891±0.024(p < 0.01,p < 0.01) 3.64±0.51(p < 0.01,p < 0.01)
T-CNN + LRM ET 0.881±0.023(p < 0.01,p < 0.01) 2.13±0.39(p < 0.01,p < 0.01)
WT 0.918±0.022(p < 0.01,p < 0.01) 2.87±0.42(p < 0.01,p < 0.01)
TC 0.884±0.025(p < 0.01,p < 0.01) 2.56±0.40(p < 0.01,p < 0.01)
ALL ET 0.899±0.020 1.12±0.25
WT 0.936±0.018 1.85±0.31
TC 0.905±0.021 1.68±0.28

5-fold cross-validation results are presented as Mean ± Standard Deviation (SD). Values in parentheses (pt-test,pwilcoxon) indicate p-values from the paired Student’s t-test and the non-parametric Wilcoxon signed-rank test, respectively, comparing the respective baseline model against the final proposed model (ALL / DiceBRD loss). Extremely small p-values are reported as p < 0.01 following standard statistical reporting guidelines.

Fig 11. Examples of the ablation experiment results of this algorithm on the BraTS2019 dataset.

Fig 11

(a): T1CE, (b): T – CNN, (c): T – CNN + GGM, (d): T – CNN + LRM, (e): T – CNN + GGM + LRM, (f): GT; WT: green + red + yellow, TC: red + yellow, ET: yellow.

To verify the effectiveness of the proposed loss function, ablation experiments were conducted. Table 5 presents the results obtained from training GL-Net with various loss functions. First, a comparison was made between Dice loss and Dice+WCE, where Dice+WCE improved the DSC by 0.5%, 0.8%, and 0.4% for the ET, WT, and TC regions, respectively, and reduced HD by 0.6 mm, 0.8 mm, and 0.84 mm, respectively. This indicates that WCE effectively mitigates the class imbalance problem. WCE refers to the use of a distance map for weighting and includes all voxels in the loss calculation. In the comparison between Dice+WCE and the proposed DiceBRD loss function, the proposed loss improved the DSC by 0.6%, 1.2%, and 0.4% for the ET, WT, and TC regions, respectively, while reducing HD by 0.18 mm, 0.61 mm, and 0.42 mm, respectively. More importantly, the dual statistical analyses rigorously validate the specific advantages of the DiceBRD loss. While the DSC improvements over Dice+WCE show moderate statistical significance (e.g., p = 0.03 for both t-test and Wilcoxon test in WT), the reductions in the Hausdorff Distance (HD) are highly significant across all subregions (p≤0.01 for ET, p < 0.01 for WT and TC in both tests). This explicitly confirms our methodological hypothesis: by strictly restricting the weighted cross-entropy calculation to the dynamically evolving boundary regions, the model successfully tightens the geometric contour alignment, leading to a statistically robust and reliable reduction in boundary errors (HD). Additionally, qualitative results, as shown in Fig 12, indicate that the proposed loss function enhances network performance and yields satisfactory experimental results, which is consistent with the quantitative comparisons in Table 5.

Table 5. Comparative experimental results of different loss functions for GL-Net on the BraTS2021 internal test set (via 5-fold cross-validation).

Method Region DSC HD
Dice ET 0.846±0.034(0.02,0.02) 2.23±0.55(p < 0.01,p < 0.01)
WT 0.899±0.031(p < 0.01,p < 0.01) 3.42±0.71(p < 0.01,p < 0.01)
TC 0.856±0.022(0.02,0.01) 2.78±0.62(p < 0.01,p < 0.01)
Dice+WCE ET 0.851±0.029(0.16,0.21) 1.63±0.42(0.01,0.01)
WT 0.907±0.028(0.03,0.03) 2.62±0.52(p < 0.01,p < 0.01)
TC 0.860±0.027(0.32,0.24) 1.94±0.48(p < 0.01,p < 0.01)
DiceBRD loss ET 0.857±0.024 1.45±0.32
WT 0.919±0.022 2.01±0.38
TC 0.864±0.025 1.52±0.35

5-fold cross-validation results are presented as Mean ± Standard Deviation (SD). Values in parentheses (pt-test,pwilcoxon) indicate p-values from the paired Student’s t-test and the non-parametric Wilcoxon signed-rank test, respectively, comparing the respective baseline model against the final proposed model (ALL / DiceBRD loss). Extremely small p-values are reported as p < 0.01 following standard statistical reporting guidelines.

Fig 12. Examples of segmentation results of the loss function proposed on the BraTS2019.

Fig 12

WT: green + red + yellow, TC: red + yellow, ET: yellow.

It is worth noting that these findings may still be influenced by characteristics of the training data. The BraTS datasets, although standardized and widely adopted, remain limited in size compared with real-world multi-center cohorts, which may constrain the generalizability of the observed improvements. Moreover, the significant class imbalance inherent to glioma subregions—particularly the small volume of the ET region—may amplify sensitivity to sampling variations, potentially affecting the magnitude of performance gains. In addition, the curated nature of BraTS introduces a degree of selection bias, meaning the effectiveness of the proposed loss function on more heterogeneous clinical data remains to be further validated. These factors should be considered when interpreting the ablation results.

VASARI-based feature analysis

While geometric metrics such as DSC and HD provide quantitative measures of spatial overlap and boundary distances, they do not fully capture the clinical utility of a segmentation model. In clinical workflows, the ultimate goal of tumor delineation is to extract reliable morphological and compositional metrics—such as the proportions of necrosis, enhancing, and non-enhancing tumor regions—that directly inform diagnosis and treatment planning. Therefore, downstream classification consistency serves as a crucial indicator of potential clinical relevance for segmentation quality. If the segmentation masks generated by GL-Net yield VASARI features and subsequent GBM diagnostic performance that are statistically indistinguishable from those derived from expert manual annotations (ground truth), it provides valuable complementary and indirect evidence that GL-Net successfully preserves the clinically critical morphological variations and subregion proportions required for accurate diagnosis, thereby bridging the gap between pixel-level accuracy and potential clinical relevance.

Following this rationale, after extracting VASARI structural imaging features from both the GL-Net-generated masks and the BraTS gold-standard masks, we constructed GBM classification models and compared the discriminative performance of the two feature sets. The results (Table 6) showed that the model based on the gold-standard masks achieved an AUC of 0.954, ACC of 0.940, and F1-score of 0.962, while the model based on GL-Net outputs achieved an AUC of 0.949, ACC of 0.925, and F1-score of 0.952, indicating highly consistent performance across all metrics (Fig 13). DeLong test further confirmed that the difference in AUC between the two models was not statistically significant (p = 0.9996).

Table 6. GBM classification performance using GL-Net vs. BraTS masks.

Mask AUC ACC F1 SEN SPE PRE
BraTS seg 0.954 0.940 0.962 0.981 0.800 0.944
GL-Net 0.949 0.925 0.952 0.962 0.800 0.943

SEN — Sensitivity; SPE — Specificity; PRE — Precision; BraTS seg — BraTS gold-standard segmentation masks.

Fig 13. ROC curves for GBM classification using GL-Net and BraTS segmentation masks.

Fig 13

In addition, visualization of the logistic regression feature weights (Fig 14) revealed that the weight distribution patterns of both models were almost identical, further demonstrating that the structural imaging features extracted from GL-Net segmentations contribute to GBM classification comparably to manual annotations. Collectively, these results suggest that GL-Net segmentation masks can serve as a stable and reliable input for GBM imaging feature extraction and diagnostic classification, offering indirect evidence of the model’s potential clinical relevance rather than definitive proof of absolute segmentation accuracy.

Fig 14. Feature weight comparison between GL-Net (left) and gold-standard masks (right).

Fig 14

Conclusion

Medical imaging plays a pivotal role in clinical diagnosis, particularly for the segmentation of brain glioma in MRI. Despite the promise of deep learning, performance is often limited by data scarcity and image complexity. In this study, we proposed GL-Net, a brain glioma segmentation algorithm that integrates deep learning with prior knowledge. The Gaussian Gating Module (GGM) effectively suppresses image noise, activates secondary features, and enhances recognition of blurred edges, while the Label Refinement Module (LRM) leverages label priors for multi-scale feature fusion, improving the perception of fine details. A dynamic weighted loss function was also designed to emphasize edge-region voxels, mitigating the class imbalance problem.

Extensive experiments on the BraTS2019 and BraTS2021 datasets demonstrate that GL-Net achieves robust and highly competitive performance, with average DSCs of 0.877 and 0.913, and HDs of 1.83 mm and 1.55 mm, respectively, achieving highly competitive performance relative to reported benchmarks, particularly in the segmentation of the Enhancing Tumor (ET) and Whole Tumor (WT) regions. To assess clinical relevance, VASARI-based structural imaging features were extracted from GL-Net segmentations and compared to features derived from BraTS gold-standard masks. GBM classification results showed no statistically significant difference (p = 0.9996) between the two feature sets, and logistic regression feature weight distributions were nearly identical, suggesting that GL-Net provides stable and clinically meaningful representations comparable to manual annotations, thus offering complementary evidence of its potential clinical relevance.

While GL-Net demonstrates strong segmentation accuracy and reliable downstream feature extraction, claims regarding its direct clinical applicability must be interpreted with caution. A primary limitation of the current study is the reliance on the highly curated BraTS datasets. Although multi-institutional, these standardized datasets may not fully capture the extreme heterogeneity, unpredictable artifacts, and diverse scanning protocols encountered in independent, real-world clinical cohorts. The absence of external validation on an independent real-world dataset means the model’s operational robustness in everyday clinical practice remains to be definitively proven. Furthermore, to address the limitations of citing unstandardized comparative results, future work will involve re-implementing state-of-the-art baseline models within a unified training, preprocessing, and evaluation framework (such as nnU-Net) to enable standardized, head-to-head benchmarking. Therefore, extensive external validation on independent clinical cohorts and subsequent prospective trials are essential next steps to rigorously evaluate the model’s true generalizability. Future work will focus on conducting these prospective validations, optimizing GL-Net for small or poorly defined tumors, and iteratively advancing its robust incorporation into clinical workflows to truly enhance diagnostic efficiency and reliability.

Acknowledgments

This research was based on Jilin Province Science and Technology Innovation Center for Multimodal Cognitive Computing and Analysis of Medical Biometrics, and the Smart Health Joint Innovation Laboratory for the New Generation of AI.

Data Availability

The datasets used in this article are the brain tumor MRI datasets (BraTS2019 and BraTS2021) published by the Perelman School of Medicine at the University of Pennsylvania and can be found at: https://www.kaggle.com/datasets/debobratachakraborty/brats2019-dataset and https://www.kaggle.com/datasets/victorfernandezalbor/brats2021dataset.

Funding Statement

This research is supported by the Development Special Project of Jilin Provincial Development and Reform Commission in 2023 (No. 2023C042-6). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Gemini L, Tortora M, Giordano P, Prudente ME, Villa A, Vargas O, et al. Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application?. J Imaging. 2023;9(4):75. doi: 10.3390/jimaging9040075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Negro A, Gemini L, Tortora M, Pace G, Iaccarino R, Marchese M, et al. VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and IDH status in brain glioma. Front Oncol. 2024;14:1449982. doi: 10.3389/fonc.2024.1449982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Guan Y, Aamir M, Rahman Z, Ali A, Abro WA, Dayo ZA. A framework for efficient brain tumor classification using MRI images. 2021. [DOI] [PubMed]
  • 4.Chen X, Wang X, Zhang K, Fung K-M, Thai TC, Moore K, et al. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022;79:102444. doi: 10.1016/j.media.2022.102444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Haq EU, Jianjun H, Li K, Haq HU, Zhang T. An MRI-based deep learning approach for efficient classification of brain tumors. J Ambient Intell Human Comput. 2021;14(6):6697–718. doi: 10.1007/s12652-021-03535-9 [DOI] [Google Scholar]
  • 6.Tandel GS, Tiwari A, Kakde OG. Performance enhancement of MRI-based brain tumor classification using suitable segmentation method and deep learning-based ensemble algorithm. Biomedical Signal Processing and Control. 2022;78:104018. doi: 10.1016/j.bspc.2022.104018 [DOI] [Google Scholar]
  • 7.Hyun CM, Kim KC, Cho HC, Choi JK, Seo JK. Framelet pooling aided deep learning network: the method to process high dimensional medical data. Mach Learn: Sci Technol. 2020;1(1):015009. doi: 10.1088/2632-2153/ab592b [DOI] [Google Scholar]
  • 8.Akbarian S, Seyyed-Kalantari L, Khalvati F, Dolatabadi E. Evaluating Knowledge Transfer in the Neural Network for Medical Images. IEEE Access. 2023;11:85812–21. doi: 10.1109/access.2023.3283216 [DOI] [Google Scholar]
  • 9.Xie X, Niu J, Liu X, Chen Z, Tang S, Yu S. A survey on incorporating domain knowledge into deep learning for medical image analysis. Med Image Anal. 2021;69:101985. doi: 10.1016/j.media.2021.101985 [DOI] [PubMed] [Google Scholar]
  • 10.Ronneberger O, Fischer P, Brox T. U-net: Convolutional networks for biomedical image segmentation. In: Medical image computing and computer-assisted intervention–MICCAI 2015: 18th international conference, Munich, Germany, October 5-9, 2015, proceedings, part III 18. Springer. 2015. 234–41. [Google Scholar]
  • 11.Xu W, Yang H, Zhang M, Cao Z, Pan X, Liu W. Brain tumor segmentation with corner attention and high-dimensional perceptual loss. Biomedical Signal Processing and Control. 2022;73:103438. doi: 10.1016/j.bspc.2021.103438 [DOI] [Google Scholar]
  • 12.Schlemper J, Oktay O, Schaap M, Heinrich M, Kainz B, Glocker B, et al. Attention gated networks: Learning to leverage salient regions in medical images. Med Image Anal. 2019;53:197–207. doi: 10.1016/j.media.2019.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Akbar AS, Fatichah C, Suciati N. Single level UNet3D with multipath residual attention block for brain tumor segmentation. Journal of King Saud University - Computer and Information Sciences. 2022;34(6):3247–58. doi: 10.1016/j.jksuci.2022.03.022 [DOI] [Google Scholar]
  • 14.Jia Z, Zhu H, Zhu J, Ma P. Two-Branch network for brain tumor segmentation using attention mechanism and super-resolution reconstruction. Comput Biol Med. 2023;157:106751. doi: 10.1016/j.compbiomed.2023.106751 [DOI] [PubMed] [Google Scholar]
  • 15.Dosovitskiy A, Beyer L, Kolesnikov A, Weissenborn D, Zhai X, Unterthiner T. An image is worth 16x16 words: Transformers for image recognition at scale. 2020. https://arxiv.org/abs/2010.11929
  • 16.Lin J, Lin J, Lu C, Chen H, Lin H, Zhao B, et al. CKD-TransBTS: Clinical Knowledge-Driven Hybrid Transformer With Modality-Correlated Cross-Attention for Brain Tumor Segmentation. IEEE Trans Med Imaging. 2023;42(8):2451–61. doi: 10.1109/TMI.2023.3250474 [DOI] [PubMed] [Google Scholar]
  • 17.Hu Z, Li L, Sui A, Wu G, Wang Y, Yu J. An efficient R-Transformer network with dual encoders for brain glioma segmentation in MR images. Biomedical Signal Processing and Control. 2023;79:104034. doi: 10.1016/j.bspc.2022.104034 [DOI] [Google Scholar]
  • 18.ZongRen L, Silamu W, Yuzhen W, Zhe W. DenseTrans: Multimodal Brain Tumor Segmentation Using Swin Transformer. IEEE Access. 2023;11:42895–908. doi: 10.1109/access.2023.3272055 [DOI] [Google Scholar]
  • 19.Yang H, Zhou T, Zhou Y, Zhang Y, Fu H. Flexible Fusion Network for Multi-Modal Brain Tumor Segmentation. IEEE J Biomed Health Inform. 2023;27(7):3349–59. doi: 10.1109/JBHI.2023.3271808 [DOI] [PubMed] [Google Scholar]
  • 20.Ting H, Liu M. Multimodal Transformer of Incomplete MRI Data for Brain Tumor Segmentation. IEEE J Biomed Health Inform. 2023;PP:10.1109/JBHI.2023.3286689. doi: 10.1109/JBHI.2023.3286689 [DOI] [PubMed] [Google Scholar]
  • 21.Wenxuan W, Chen C, Meng D, Hong Y, Sen Z, Jiangyun L. Transbts: Multimodal brain tumor segmentation using transformer. In: International Conference on Medical Image Computing and Computer-Assisted Intervention, Springer. 2021. 109–19. [Google Scholar]
  • 22.Liang J, Yang C, Zeng M, Wang X. TransConver: transformer and convolution parallel network for developing automatic brain tumor segmentation in MRI images. Quant Imaging Med Surg. 2022;12(4):2397–415. doi: 10.21037/qims-21-919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhu Z, He X, Qi G, Li Y, Cong B, Liu Y. Brain tumor segmentation based on the fusion of deep semantics and edge information in multimodal MRI. Information Fusion. 2023;91:376–87. doi: 10.1016/j.inffus.2022.10.022 [DOI] [Google Scholar]
  • 24.Liu Y, Duan Y, Zeng T. Learning multi-level structural information for small organ segmentation. Signal Processing. 2022;193:108418. doi: 10.1016/j.sigpro.2021.108418 [DOI] [Google Scholar]
  • 25.Lin T-Y, Goyal P, Girshick R, He K, Dollar P. Focal Loss for Dense Object Detection. In: 2017 IEEE International Conference on Computer Vision (ICCV), 2017. 2999–3007. 10.1109/iccv.2017.324 [DOI]
  • 26.Caliva F, Iriondo C, Martinez AM, Majumdar S, Pedoia V. Distance map loss penalty term for semantic segmentation. arXiv preprint. 2019. doi: 10.48550/arXiv.1908.03679 [DOI] [Google Scholar]
  • 27.Kervadec H, Bouchtiba J, Desrosiers C, Granger E, Dolz J, Ayed IB. In: International conference on medical imaging with deep learning, 2019. 285–96.
  • 28.Karimi D, Salcudean SE. Reducing the Hausdorff Distance in Medical Image Segmentation With Convolutional Neural Networks. IEEE Trans Med Imaging. 2020;39(2):499–513. doi: 10.1109/TMI.2019.2930068 [DOI] [PubMed] [Google Scholar]
  • 29.Yeung M, Sala E, Schönlieb C-B, Rundo L. Unified Focal loss: Generalising Dice and cross entropy-based losses to handle class imbalanced medical image segmentation. Comput Med Imaging Graph. 2022;95:102026. doi: 10.1016/j.compmedimag.2021.102026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Du J, Guan K, Liu P, Li Y, Wang T. Boundary-Sensitive Loss Function With Location Constraint for Hard Region Segmentation. IEEE J Biomed Health Inform. 2023;27(2):992–1003. doi: 10.1109/JBHI.2022.3222390 [DOI] [PubMed] [Google Scholar]
  • 31.Yu S, Zhang B, Xiao J, Lim EG. Structure-Consistent Weakly Supervised Salient Object Detection with Local Saliency Coherence. AAAI. 2021;35(4):3234–42. doi: 10.1609/aaai.v35i4.16434 [DOI] [Google Scholar]
  • 32.Wang G, Lu H, Li N, Xue H, Sang P. Kfd-net: a knowledge fusion decision method for post-processing brain glioma MRI segmentation. Pattern Anal Applic. 2024;27(4). doi: 10.1007/s10044-024-01343-3 [DOI] [Google Scholar]
  • 33.Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby JS, et al. Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features. Sci Data. 2017;4:170117. doi: 10.1038/sdata.2017.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bakas S, Reyes M, Jakab A, Bauer S, Rempfler M, Crimi A, et al. Identifying the best machine learning algorithms for brain tumor segmentation, progression assessment, and overall survival prediction in the BRATS challenge. 2018. 10.48550/arXiv.1811.02629 [DOI]
  • 35.Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby J. Segmentation labels and radiomic features for the pre-operative scans of the TCGA-LGG collection. The Cancer Imaging Archive. 2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rehman MU, Ryu J, Nizami IF, Chong KT. RAAGR2-Net: A brain tumor segmentation network using parallel processing of multiple spatial frames. Comput Biol Med. 2023;152:106426. doi: 10.1016/j.compbiomed.2022.106426 [DOI] [PubMed] [Google Scholar]
  • 37.Chang Y, Zheng Z, Sun Y, Zhao M, Lu Y, Zhang Y. DPAFNet: A Residual Dual-Path Attention-Fusion Convolutional Neural Network for Multimodal Brain Tumor Segmentation. Biomedical Signal Processing and Control. 2023;79:104037. doi: 10.1016/j.bspc.2022.104037 [DOI] [Google Scholar]
  • 38.AboElenein NM, Piao S, Noor A, Ahmed PN. MIRAU-Net: An improved neural network based on U-Net for gliomas segmentation. Signal Processing: Image Communication. 2022;101:116553. doi: 10.1016/j.image.2021.116553 [DOI] [Google Scholar]
  • 39.Mazumdar I, Mukherjee J. Fully automatic MRI brain tumor segmentation using efficient spatial attention convolutional networks with composite loss. Neurocomputing. 2022;500:243–54. doi: 10.1016/j.neucom.2022.05.050 [DOI] [Google Scholar]

Decision Letter 0

Mario Tortora

16 Oct 2025

-->PONE-D-25-43663-->-->GL-Net: Gaussian-Gated and Layered Refinement Algorithm for MRI Segmentation of Brain Gliomas-->-->PLOS ONE

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 30 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mario Tortora, Pd.D.s, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

-->1. When submitting your revision, we need you to address these additional requirements.-->--> -->-->Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at -->-->https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and -->-->https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf-->--> -->-->2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.-->--> -->-->3. Thank you for stating in your Funding Statement: -->-->This research is supported by the Development Special Project of Jilin Provincial Development and Reform Commission in 2023 (No. 2023C042-6). -->--> -->-->Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. -->-->Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.-->--> -->-->4. Thank you for uploading your study's underlying data set. Unfortunately, the repository you have noted in your Data Availability statement does not qualify as an acceptable data repository according to PLOS's standards.-->--> -->-->At this time, please upload the minimal data set necessary to replicate your study's findings to a stable, public repository (such as figshare or Dryad) and provide us with the relevant URLs, DOIs, or accession numbers that may be used to access these data. For a list of recommended repositories and additional information on PLOS standards for data deposition, please see https://journals.plos.org/plosone/s/recommended-repositories.-->--> -->-->5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

This manuscript presents a technically interesting and potentially impactful approach to 3D glioblastoma segmentation using a hybrid transformer–CNN architecture. However, its clinical positioning remains underdeveloped. The authors are strongly encouraged to better contextualize their model within current clinical practice by integrating relevant literature and aligning their discussion with existing radiological evaluation frameworks. Further comparison with prior models will also be necessary to objectively assess the proposed method’s contribution to the field.

Title:

The title is clear and informative, but could be further strengthened by explicitly highlighting the methodological innovation introduced in the paper, to better convey its novelty and relevance compared to existing literature.

Abstract:

The abstract is well written and provides a coherent summary of the study. However, it would benefit from the inclusion of more specific performance results and a brief mention of the potential clinical implications of the proposed method, in order to emphasize its real-world utility.

Introduction:

The introduction is well structured and successfully establishes the clinical relevance of accurate glioblastoma segmentation. That said, to improve scientific depth and contextual clarity, the background section should be expanded to include more details on current radiological assessment frameworks commonly used in clinical practice for glioma characterization. Including references to standardized descriptors would strengthen the clinical foundation of the work and better justify the need for automated approaches.

Materials and Methods:

The methodology is described in sufficient detail. However, clarification is needed on whether the dataset reflects adequate clinical and technical heterogeneity (e.g., use of different MRI scanners and acquisition protocols), to ensure that the proposed model generalizes well across varying real-world conditions.

Statistical Analysis:

The statistical analysis is sound and appropriately rigorous. Nonetheless, the authors should discuss potential limitations related to dataset size, class imbalance, or selection bias, and how these factors may have influenced the results.

Results:

The results are clearly presented. However, a more direct and quantitative comparison with existing models is encouraged—ideally through a summary table—to help readers appreciate the degree of improvement introduced by the proposed method.

Discussion:

The discussion effectively highlights the main contributions of the work, but it would benefit from a more critical integration of recent literature, particularly studies that bridge conventional MRI evaluation and computational methods. Including references to structured radiological reporting tools and lexicons currently used in glioma assessment would enhance the discussion and help demonstrate how the proposed model might complement existing clinical workflows.

Conclusion:

The conclusions are consistent with the reported results. However, they should more explicitly acknowledge that implementation in clinical practice requires further validation, particularly in relation to how the model correlates with standard radiological evaluation criteria. The authors should stress that clinical translation depends on how well the algorithm integrates with expert visual assessment and standardized MRI descriptors.

Figures, Tables, and Diagrams:

Figures and tables are high quality, well-designed, and clearly aid in data interpretation. It may be useful to add a practical example or visual workflow illustrating how the model could be integrated into a clinical imaging pipeline.

References:

The references are appropriate and up to date. However, to further strengthen the clinical relevance of the work, it is recommended that the authors include recent studies that explore the use of structured MRI descriptors and visual rating systems for glioma grading and molecular status prediction, especially those based on conventional imaging protocols.

-->--> -->-->[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions-->

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1:   Clear and concise title.

The well-written and comprehensive abstract describes the submitted scientific work in its entirety, providing references to the scientific background and clarifying the study hypotheses.

The well-structured introduction. Glioblastoma is a highly malignant brain tumor, and accurate lesion segmentation on imaging plays a crucial role in the diagnosis, treatment, and follow-up of glioblastoma. The challenge of this work is to propose a 3D segmentation method for glioblastoma MRI, GL-Net. This method employs an improved hybrid architecture that integrates a transformer and a CNN (T-CNN), integrating knowledge-based features into traditional data-driven approaches.

The materials and methods are well described.

The statistical analysis is thorough and rigorous.

The results are presented clearly and comprehensively.

In the discussion, they are analyzed point by point and compared with other similar articles recently published on the topic, highlighting the strengths and major innovations emerging from the submitted paper.

The conclusions are supported by the results and appear interesting.

Detailed and appropriate tables, graphs, and diagrams make understanding easier and faster.

Well-curated images.

Appropriate bibliographic references are provided, including references to the most recent major scientific articles published on the topic.

I suggest including in the discussion or in the conclusion that the proposed method for the automatic 3D segmentation of brain gliomas must be implemented in daily clinical practice and must be correlated with the clinical radiological assessment based on the identification of various MRI characteristics, first and foremost those of the conventional MRI examination, such as those codified by the so-called VASARI lexicon

(Below I report some bibliographical references on the topic: “VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and IDH status in brain glioma. Negro A, Gemini L, Tortora M, Pace G, Iaccarino R, Marchese M, Elefante A, Tortora F, D'Agostino V; members of ODM Multidisciplinary Neuro-Oncology Group. Front Oncol. 2024 Dec 23;14:1449982. doi: 10.3389/fonc.2024.1449982. eCollection 2024. PMID: 39763601; “Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application? Gemini L, Tortora M, Giordano P, Prudente ME, Villa A, Vargas O, Giugliano MF, Somma F, Marchello G, Chiaramonte C, Gaetano M, Frio F, Di Giorgio E, D'Avino A, Tortora F, D'Agostino V, Negro A. J Imaging. 2023 Mar 24;9(4):75. doi: 10.3390/jimaging9040075. PMID: 37103226”).

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?   For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: Yes:   Alberto Negro

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2026 Jun 22;21(6):e0351953. doi: 10.1371/journal.pone.0351953.r002

Author response to Decision Letter 1


17 Nov 2025

Dear Editors and Reviewers,

We express our sincere gratitude to you and your colleagues for reviewing our submitted manuscript and providing valuable comments and suggestions. We highly appreciate these invaluable suggestions and believe they have played a crucial role in our research. We have carefully considered each of your suggestions, conducting thorough revisions to ensure the academic and methodological accuracy and credibility of our paper. Here, we sincerely respond to your review comments, hoping that our responses meet your expectations. Once again, we thank you for your valuable feedback and patience. Below are our responses to the specific comments:

Additional Editor Comments:

“This manuscript presents a technically interesting and potentially impactful approach to 3D glioblastoma segmentation using a hybrid transformer–CNN architecture. However, its clinical positioning remains underdeveloped. The authors are strongly encouraged to better contextualize their model within current clinical practice by integrating relevant literature and aligning their discussion with existing radiological evaluation frameworks. Further comparison with prior models will also be necessary to objectively assess the proposed method’s contribution to the field.

Title:

The title is clear and informative, but could be further strengthened by explicitly highlighting the methodological innovation introduced in the paper, to better convey its novelty and relevance compared to existing literature.

Abstract:

The abstract is well written and provides a coherent summary of the study. However, it would benefit from the inclusion of more specific performance results and a brief mention of the potential clinical implications of the proposed method, in order to emphasize its real-world utility.

Introduction:

The introduction is well structured and successfully establishes the clinical relevance of accurate glioblastoma segmentation. That said, to improve scientific depth and contextual clarity, the background section should be expanded to include more details on current radiological assessment frameworks commonly used in clinical practice for glioma characterization. Including references to standardized descriptors would strengthen the clinical foundation of the work and better justify the need for automated approaches.

Materials and Methods:

The methodology is described in sufficient detail. However, clarification is needed on whether the dataset reflects adequate clinical and technical heterogeneity (e.g., use of different MRI scanners and acquisition protocols), to ensure that the proposed model generalizes well across varying real-world conditions.

Statistical Analysis:

The statistical analysis is sound and appropriately rigorous. Nonetheless, the authors should discuss potential limitations related to dataset size, class imbalance, or selection bias, and how these factors may have influenced the results.

Results:

The results are clearly presented. However, a more direct and quantitative comparison with existing models is encouraged—ideally through a summary table—to help readers appreciate the degree of improvement introduced by the proposed method.

Discussion:

The discussion effectively highlights the main contributions of the work, but it would benefit from a more critical integration of recent literature, particularly studies that bridge conventional MRI evaluation and computational methods. Including references to structured radiological reporting tools and lexicons currently used in glioma assessment would enhance the discussion and help demonstrate how the proposed model might complement existing clinical workflows.

Conclusion:

The conclusions are consistent with the reported results. However, they should more explicitly acknowledge that implementation in clinical practice requires further validation, particularly in relation to how the model correlates with standard radiological evaluation criteria. The authors should stress that clinical translation depends on how well the algorithm integrates with expert visual assessment and standardized MRI descriptors.”

Reply to Additional Editor:

It is our great honor that our work has been recognized by the editors, and we sincerely appreciate the constructive comments provided. Below, we provide our responses to the suggestions for each section.

Response regarding the title:

To better highlight the methodological innovation and emphasize the novelty of our approach, we have revised the title to explicitly reflect the integration of prior knowledge and the key technical modules (Gaussian-Gated and Layered Refinement). The revised title now reads: “GL-Net: A Knowledge-Guided Gaussian-Gated and Layered Refinement Network for 3D MRI Segmentation of Brain Gliomas.” This modification better conveys the methodological contribution of our work while keeping the title concise and informative.

Response regarding the abstract:

To better emphasize the real-world applicability and performance of our proposed method, we have revised the abstract to include the quantitative analysis results based on VASARI features extracted from the segmentation outputs. We also briefly highlighted the potential clinical significance of GL-Net in supporting accurate glioma diagnosis and treatment planning. The revised abstract now provides clearer evidence of the model’s effectiveness and clinical relevance.

Response regarding Materials and Methods:

In the revised section, we have added a detailed description of the datasets used, including data sources, imaging device manufacturers, magnetic field strength ranges, and relevant imaging protocols. These additions ensure that the proposed model can be well generalized across diverse real-world conditions.

Response regarding statistical analysis:

This is an excellent suggestion. The issues raised—such as dataset size, class imbalance, and selection bias—are indeed among the key challenges that our work aims to address. Following the editors’ recommendation, we have incorporated additional content in the Results section to specifically discuss these aspects.

Response regarding the Results:

We have optimized the presentation of the summary tables and added new figures to illustrate the results. We believe these additions will help readers more intuitively understand the extent of improvements achieved by the proposed method.

Response regarding the Discussion and Conclusion:

In these two sections, we have added content on the quantitative VASARI evaluation of segmentation masks produced by our model compared with the gold-standard masks delineated by clinicians. The results demonstrate that the proposed model holds substantial potential and utility in supporting clinical practice and subsequent research.

Response regarding Figures, Tables, and Diagrams:

In the Methods section, we have added a workflow diagram to illustrate how the model can be integrated into the clinical workflow.

Response regarding References:

We have added new references in the manuscript concerning the use of structured MRI descriptors and the VASARI visual assessment system for glioma grading.

Reviewer #1: I suggest including in the discussion or in the conclusion that the proposed method for the automatic 3D segmentation of brain gliomas must be implemented in daily clinical practice and must be correlated with the clinical radiological assessment based on the identification of various MRI characteristics, first and foremost those of the conventional MRI examination, such as those codified by the so-called VASARI lexicon.

Reply to Reviewer 1:

Thank you very much for your careful review and approval of our paper. The suggestions and viewpoints you provided have played a crucial guiding role in our research. Here are our responses to specific comments:

Following your suggestion, we conducted additional experiments to further evaluate the clinical applicability of our method. Specifically, we extracted F4–F7 structural imaging features based on the VASARI scoring system from both GL-Net segmentation outputs and the gold-standard masks. This allowed us to assess the consistency and reliability of the model’s segmentation results in the context of GBM clinical characterization, and to verify that the model’s support for clinical diagnosis is comparable to manual annotation.

The results showed that, after extracting VASARI structural imaging features from both GL-Net and BraTS gold-standard masks, we built GBM classification models and compared the discriminative performance of the two feature sets. The model based on gold-standard masks achieved an AUC of 0.954, ACC of 0.940, and F1 score of 0.962, whereas the model based on GL-Net outputs achieved an AUC of 0.949, ACC of 0.925, and F1 score of 0.952, demonstrating a high degree of consistency across all metrics. DeLong’s test further indicated that the difference in AUC between the two models was not statistically significant (p = 0.9996).

Additionally, we visualized the feature weights of the logistic regression models (Figure X) and observed that the weight distribution patterns were nearly identical between the two models. This further confirms that the structural imaging features derived from GL-Net segmentations contribute to GBM classification in a manner highly consistent with manual annotations.

In summary, the GL-Net segmentation masks provide stable and reliable structural imaging features for GBM clinical feature extraction and diagnostic discrimination, demonstrating comparable performance to manual gold-standard masks. These findings indicate that GL-Net has strong potential for integration into daily clinical practice, supporting radiological assessment based on MRI characteristics, including those codified by the VASARI lexicon, and facilitating accurate and efficient clinical decision-making.

Sincerely,

Huimin Lu

Attachment

Submitted filename: Response to Reviewers.docx

pone.0351953.s001.docx (20.1KB, docx)

Decision Letter 1

Taikyeong Jeong

19 Feb 2026

-->PONE-D-25-43663R1-->-->GL-Net: A Knowledge-Guided Gaussian-Gated and Layered Refinement Network for 3D MRI Segmentation of Brain Gliomas-->-->PLOS One

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Although the manuscript presents a technically sound and well-structured study, several issues may warrant minor revision.

While the manuscript reports improvements in DSC and HD metrics, no statistical significance testing is provided to support these performance gains. Given that some improvements are relatively modest in magnitude, it would be important to demonstrate whether the reported differences are statistically significant across folds. Reporting mean ± standard deviation and including appropriate paired statistical tests (e.g., paired t-test or Wilcoxon signed-rank test) would strengthen the robustness of the conclusions.

Tables 1 and 2 compare GL-Net with several existing models. However, it is not clearly stated whether these models were re-implemented under identical preprocessing and cross-validation settings, or whether the results were directly cited from the original publications. This distinction is important for assessing fairness and reproducibility. Explicit clarification of the comparison protocol would improve methodological transparency.

The mathematical formulation of the DiceBRD loss function requires clearer explanation. In particular, the relationship between the ROI-based region restriction and the combined Dice and weighted cross-entropy terms could be more explicitly described. Additionally, certain variable definitions appear repetitive or ambiguous. A more precise and structured presentation of the loss formulation would enhance technical clarity.

The manuscript evaluates segmentation performance indirectly through downstream GBM classification using selected VASARI features. While the reported consistency between GL-Net-derived and ground-truth-derived features is encouraging, the manuscript could more clearly articulate how classification consistency serves as a direct validation of segmentation quality. A brief clarification of this methodological rationale would strengthen the interpretability of the clinical validation.

Although the manuscript discusses clinical integration and workflow applicability, no external validation on independent real-world cohorts is provided. The current evaluation is limited to curated BraTS datasets. The claims regarding clinical applicability should be interpreted in light of this limitation, and a brief acknowledgment of the need for further prospective validation may improve balance.

For full reproducibility, additional implementation details would be helpful. The manuscript does not specify the computational environment (e.g., GPU type), training time, inference time, or model parameter size. Including these details would improve transparency and practical reproducibility.

The manuscript refers to the “BraTS2021 test set,” while also stating that five-fold cross-validation was performed. Since official test labels are not publicly available in BraTS challenges, the terminology should be clarified to avoid confusion regarding evaluation protocol.

The manuscript demonstrates solid technical contribution and meaningful clinical contextualization. The issues raised above do not undermine the validity of the study but relate primarily to clarity, statistical rigor, and methodological transparency.

==============================

Please submit your revised manuscript by Apr 05 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Taikyeong Ted Jeong, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Although the manuscript presents a technically sound and well-structured study, several issues may warrant minor revision.

While the manuscript reports improvements in DSC and HD metrics, no statistical significance testing is provided to support these performance gains. Given that some improvements are relatively modest in magnitude, it would be important to demonstrate whether the reported differences are statistically significant across folds. Reporting mean ± standard deviation and including appropriate paired statistical tests (e.g., paired t-test or Wilcoxon signed-rank test) would strengthen the robustness of the conclusions.

Tables 1 and 2 compare GL-Net with several existing models. However, it is not clearly stated whether these models were re-implemented under identical preprocessing and cross-validation settings, or whether the results were directly cited from the original publications. This distinction is important for assessing fairness and reproducibility. Explicit clarification of the comparison protocol would improve methodological transparency.

The mathematical formulation of the DiceBRD loss function requires clearer explanation. In particular, the relationship between the ROI-based region restriction and the combined Dice and weighted cross-entropy terms could be more explicitly described. Additionally, certain variable definitions appear repetitive or ambiguous. A more precise and structured presentation of the loss formulation would enhance technical clarity.

The manuscript evaluates segmentation performance indirectly through downstream GBM classification using selected VASARI features. While the reported consistency between GL-Net-derived and ground-truth-derived features is encouraging, the manuscript could more clearly articulate how classification consistency serves as a direct validation of segmentation quality. A brief clarification of this methodological rationale would strengthen the interpretability of the clinical validation.

Although the manuscript discusses clinical integration and workflow applicability, no external validation on independent real-world cohorts is provided. The current evaluation is limited to curated BraTS datasets. The claims regarding clinical applicability should be interpreted in light of this limitation, and a brief acknowledgment of the need for further prospective validation may improve balance.

For full reproducibility, additional implementation details would be helpful. The manuscript does not specify the computational environment (e.g., GPU type), training time, inference time, or model parameter size. Including these details would improve transparency and practical reproducibility.

The manuscript refers to the “BraTS2021 test set,” while also stating that five-fold cross-validation was performed. Since official test labels are not publicly available in BraTS challenges, the terminology should be clarified to avoid confusion regarding evaluation protocol.

The manuscript demonstrates solid technical contribution and meaningful clinical contextualization. The issues raised above do not undermine the validity of the study but relate primarily to clarity, statistical rigor, and methodological transparency.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

Reviewer #4: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #2:   The author have already met the requirements above, and I suppose the essay should be accepted. Furthermore, I believe that this essay involves reasonable innovations.

Reviewer #3:   The manuscript is scientifically rigorous and suitable for PLOS ONE, with strong potential impact in medical image analysis. However, revisions are needed to address benchmarking limitations, enhance reproducibility (e.g., release code), and provide more cautious interpretation of results. Resubmit with clarified comparisons to official BraTS metrics where possible, and consider external validation on a small held-out cohort if feasible.

Reviewer #4:   The authors answered satisfactory to previous Referee report, however they do not take into account the role of the environmental noise. See the attached report.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?   For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #2: No

Reviewer #3: Yes:   Norhan S ElMongy

Reviewer #4: Yes:   Bernardo Spagnolo

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Attachment

Submitted filename: Reveiwers suggestions for this essay.doc

pone.0351953.s002.doc (24KB, doc)
Attachment

Submitted filename: Report_PONE-D-25-43663_R1_17.02.26 .pdf

pone.0351953.s003.pdf (135KB, pdf)
PLoS One. 2026 Jun 22;21(6):e0351953. doi: 10.1371/journal.pone.0351953.r004

Author response to Decision Letter 2


17 Mar 2026

Response to Reviewers

Dear Editors and Reviewers,

We express our sincere gratitude to you and your colleagues for reviewing our submitted manuscript and providing valuable comments and suggestions. We highly appreciate these invaluable suggestions and believe they have played a crucial role in our research. We have carefully considered each of your suggestions, conducting thorough revisions to ensure the academic and methodological accuracy and credibility of our paper. Here, we sincerely respond to your review comments, hoping that our responses meet your expectations. Once again, we thank you for your valuable feedback and patience. Below are our responses to the specific comments:

1. Reviewer's Comment: “While the manuscript reports improvements in DSC and HD metrics, no statistical significance testing is provided to support these performance gains. Given that some improvements are relatively modest in magnitude, it would be important to demonstrate whether the reported differences are statistically significant across folds. Reporting mean ± standard deviation and including appropriate paired statistical tests (e.g., paired t-test or Wilcoxon signed-rank test) would strengthen the robustness of the conclusions.”

Response: We sincerely thank the reviewer for this rigorous and crucial suggestion. We completely agree that relying solely on average metrics is insufficient to prove the absolute superiority of the model, and that statistical significance testing is essential to confirm that the observed improvements are robust across different cross-validation folds. Following your valuable advice, we have comprehensively updated our quantitative evaluation:

1. We have revised the result tables (specifically the ablation study tables, e.g., Tables 3, 4, and 5) to report all metrics in the format of Mean ± Standard Deviation (SD) across the five-fold cross-validation. Furthermore, we conducted paired t-tests to compare the baseline models with our proposed GL-Net. The resulting p-values are now included in the tables (values in parentheses), where p<0.01 indicates high statistical significance. The results confirm that our performance gains, even those with smaller margins, are indeed statistically significant.

2. To formally document this statistical evaluation, we have added a dedicated paragraph to the “Dataset and evaluation metrics” section in the revised manuscript: “Furthermore, to rigorously validate the performance improvements of the proposed GL-Net, statistical significance testing was conducted. The quantitative segmentation results across the five-fold cross-validation are reported as Mean ± Standard Deviation (SD). A paired Student’s t-test was utilized to determine whether the performance differences between the baseline configurations (or comparative models) and the proposed GL-Net were statistically significant across the test folds. A p-value of <0.05 was considered statistically significant, and p<0.01 was considered highly significant.”

3. In addition to updating the tables with Mean ± SD and p-values, we have also expanded the text in the ‘Ablation experiments’ section to deeply analyze these statistical findings. Most notably, in the analysis of our proposed DiceBRD loss function (Table 5), we explicitly highlighted that while the overall volume overlap (DSC) showed moderate improvements, the reductions in boundary errors (Hausdorff Distance) were highly statistically significant (p≤0.01). This statistical evidence perfectly corroborates our methodological claim that the dynamic boundary weighting specifically and robustly refines fuzzy edge contours.

2. Reviewer's Comment: “Tables 1 and 2 compare GL-Net with several existing models. However, it is not clearly stated whether these models were re-implemented under identical preprocessing and cross-validation settings, or whether the results were directly cited from the original publications. This distinction is important for assessing fairness and reproducibility. Explicit clarification of the comparison protocol would improve methodological transparency.”

Response: We sincerely thank the reviewer for pointing out this important detail regarding methodological transparency. We completely agree that clarifying the evaluation protocol is crucial for fairness and reproducibility.

We would like to clarify that the quantitative results of the comparative models presented in Tables 1 and 2 were directly cited from their respective original publications, rather than being re-implemented under our exact preprocessing and cross-validation conditions. To ensure transparency, we have added explicit statements to the revised manuscript acknowledging this.

Specifically, we have updated the text in the "Comparative Experiments of GL-Net" section to read: "It is important to note that the quantitative results of the comparative models presented in these tables are directly cited from their respective original publications rather than re-implemented in our exact experimental environment. While this provides a comprehensive benchmark against current state-of-the-art methods, we acknowledge that minor variations in data splits (e.g., cross-validation folds) and preprocessing pipelines among these original studies may exist."

Additionally, we have added a clarifying note to the footer of both Table 1 and Table 2: "The performance metrics of the compared models are directly cited from their original publications."

3. Reviewer's Comment: “The mathematical formulation of the DiceBRD loss function requires clearer explanation. In particular, the relationship between the ROI-based region restriction and the combined Dice and weighted cross-entropy terms could be more explicitly described. Additionally, certain variable definitions appear repetitive or ambiguous. A more precise and structured presentation of the loss formulation would enhance technical clarity.”

Response: We sincerely thank the reviewer for this highly constructive and precise feedback. We agree that the mathematical formulation of the DiceBRD loss function in the original manuscript lacked sufficient rigor and contained typographical ambiguities.

In the revised manuscript, we have comprehensively restructured the presentation of the DiceBRD loss to ensure technical clarity:

1. We have corrected the typographical error where y_ic was ambiguously defined twice. It is now correctly defined as the ground truth one-hot encoding (y_ic∈{0,1}), while p_ic∈[0,1] is strictly defined as the predicted probability.

2. We replaced the vague terms N and voxels with standard set notations. We now use R to denote the dynamically extracted boundary region of interest, ∣R∣ for its cardinality (number of voxels), and V to denote the set of all voxels in the entire image volume.

3. We explicitly clarified the relationship between the two loss terms. The revised text now clearly states that the Dice loss term operates on the global domain V to capture overall topological structure and mitigate class imbalance, whereas the dynamic weighted cross-entropy term (L_BRD) is strictly restricted to the local boundary domain R (i∈R). This decoupling explains why the combination is highly effective at refining fuzzy edges without losing global context.

4. Reviewer's Comment: “The manuscript evaluates segmentation performance indirectly through downstream GBM classification using selected VASARI features. While the reported consistency between GL-Net-derived and ground-truth-derived features is encouraging, the manuscript could more clearly articulate how classification consistency serves as a direct validation of segmentation quality. A brief clarification of this methodological rationale would strengthen the interpretability of the clinical validation.”

Response: We sincerely thank the reviewer for this insightful comment. We completely agree that explicitly stating the methodological rationale strengthens the logical link between our downstream clinical task and the upstream segmentation quality.

While geometric evaluation metrics (such as DSC and HD) are standard for assessing pixel-level spatial overlap, they do not necessarily reflect the clinical utility of the segmentation. In clinical practice, the key requirement of tumor segmentation is to accurately capture the structural and compositional features (e.g., the proportions of necrosis, enhancing, and non-enhancing subregions) that directly drive diagnostic decisions. Because the extraction of VASARI features heavily relies on the precise morphological boundaries and volume ratios of these subregions, achieving highly consistent downstream classification performance (and identical feature weight distributions) using GL-Net-generated masks compared to expert manual annotations (ground truth) directly proves that GL-Net accurately preserves clinically relevant morphological variations. This translates geometric accuracy into genuine clinical reliability.

To make this rationale clear to the readers, we have added an explanatory paragraph at the beginning of the "VASARI-based Feature Analysis" subsection in the revised manuscript:

"While geometric metrics such as DSC and HD provide quantitative measures of spatial overlap and boundary distances, they do not fully capture the clinical utility of a segmentation model. In clinical workflows, the ultimate goal of tumor delineation is to extract reliable morphological and compositional metrics—such as the proportions of necrosis, enhancing, and non-enhancing tumor regions—that directly inform diagnosis and treatment planning. Therefore, downstream classification consistency serves as a crucial clinical validation of segmentation quality. If the segmentation masks generated by GL-Net yield VASARI features and subsequent GBM diagnostic performance that are statistically indistinguishable from those derived from expert manual annotations (ground truth), it directly demonstrates that GL-Net successfully preserves the clinically critical morphological variations and subregion proportions required for accurate diagnosis, thereby bridging the gap between pixel-level accuracy and clinical reliability."

5. Reviewer's Comment: “Although the manuscript discusses clinical integration and workflow applicability, no external validation on independent real-world cohorts is provided. The current evaluation is limited to curated BraTS datasets. The claims regarding clinical applicability should be interpreted in light of this limitation, and a brief acknowledgment of the need for further prospective validation may improve balance.”

Response: We sincerely thank the reviewer for highlighting this critical limitation. We completely agree that performing well on curated public datasets, such as BraTS, does not automatically guarantee equivalent robustness in noisy, uncurated, real-world clinical environments. Our previous claims regarding clinical applicability were perhaps too optimistic without emphasizing this necessary caveat.

To provide a more balanced and scientifically rigorous perspective, we have tempered our claims regarding direct clinical applicability and explicitly acknowledged the lack of independent external validation as a primary limitation of our current study.

Specifically, we have substantially revised the final paragraph of the Conclusion section to read:

"While GL-Net demonstrates strong segmentation accuracy and reliable downstream feature extraction, claims regarding its direct clinical applicability must be interpreted with caution. A primary limitation of the current study is the reliance on the highly curated BraTS datasets. Although multi-institutional, these standardized datasets may not fully capture the extreme heterogeneity, unpredictable artifacts, and diverse scanning protocols encountered in independent, real-world clinical cohorts. The absence of external validation on an independent real-world dataset means the model's operational robustness in everyday clinical practice remains to be definitively proven. Therefore, extensive external validation on independent clinical cohorts and subsequent prospective trials are essential next steps to rigorously evaluate the model's true generalizability..."

6. Reviewer's Comment: “For full reproducibility, additional implementation details would be helpful. The manuscript does not specify the computational environment (e.g., GPU type), training time, inference time, or model parameter size. Including these details would improve transparency and practical reproducibility.”

Response: We sincerely thank the reviewer for this highly practical and constructive suggestion. We completely agree that detailing the computational environment, model size, and time efficiency is essential for ensuring full transparency and reproducibility, as well as for evaluating the feasibility of clinical deployment.

In response to your valuable feedback, we have updated the "Experimental Setup and Preprocessing" section of the revised manuscript to include all the requested implementation details. Specifically, we have added the following information:

"All experiments were conducted on an Ubuntu operating system equipped with an Intel(R) Xeon(R) CPU E5-2678 v3 @ 2.50GHz, 128 GB of system RAM, and dual NVIDIA RTX 3090 Ti GPUs (24 GB VRAM each) …"

7. Reviewer's Comment: “The manuscript refers to the ‘BraTS2021 test set,’ while also stating that five-fold cross-validation was performed. Since official test labels are not publicly available in BraTS challenges, the terminology should be clarified to avoid confusion regarding evaluation protocol.”

Response: We sincerely thank the reviewer for pointing out this terminological ambiguity. To avoid any confusion, we would like to clarify that because the official validation and test set ground truths are not publicly available, all evaluations in our study were conducted exclusively on the official BraTS training datasets. The "test sets" mentioned in our original manuscript were, in fact, the internal hold-out test folds generated during our five-fold cross-validation process on the official training data.

To ensure absolute clarity regarding our evaluation protocol, we have thoroughly revised the terminology throughout the manuscript:

1. In the "Dataset and evaluation metrics" section, we added an explicit statement: "Since the ground truth labels for the official validation and test sets of BraTS2019 and BraTS2021 are withheld by the challenge organizers and are not publicly available, all models in this study were trained and evaluated exclusively on the official training datasets. To ensure a robust and fair evaluation, a five-fold cross-validation strategy was performed. Therefore, any reference to "test set" or "test results" in this paper specifically denotes the internal hold-out test folds partitioned during this cross-validation process, rather than the official unseen BraTS test sets."

2. In the "Comparative Experiments of GL-Net" section and table captions (e.g., Table 5), we replaced the misleading phrase "BraTS test set" with "internal hold-out test sets" or "internal test set".

Once again, we would like to express our deepest appreciation to the Editors and the Reviewers for their time, expertise, and highly constructive feedback. By addressing your insightful comments—specifically by incorporating rigorous statistical significance testing, clarifying mathematical formulations, providing detailed implementation metrics, standardizing our evaluation terminology, and offering a more balanced discussion on clinical applicability—we believe the methodological transparency, scientific rigor, and overall quality of our manuscript have been substantially elevated.

We hope that these comprehensive revisions satisfactorily address all your concerns and that the revised manuscript is now deemed suitable for publication in your journal. We remain fully available should you require any further clarifications or modifications.

Sincerely,

Huimin Lu

Attachment

Submitted filename: Response_to_Reviewers_auresp_2.docx

pone.0351953.s004.docx (25KB, docx)

Decision Letter 2

Taikyeong Jeong

9 Apr 2026

-->PONE-D-25-43663R2-->-->GL-Net: A Knowledge-Guided Gaussian-Gated and Layered Refinement Network for 3D MRI Segmentation of Brain Gliomas-->-->PLOS One

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only   the individual author can complete the verification step; PLOS staff cannot   verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Taikyeong Ted Jeong, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

At this point, the authors have provided a detailed and well-structured response to the reviewer comments.

The rebuttal is generally thorough, respectful, and demonstrates a clear effort to revise the manuscript accordingly. Most concerns raised in the previous round have been addressed to a reasonable extent.

However, while the revision has improved the manuscript, several issues remain insufficiently resolved or would benefit from further clarification.

The authors have incorporated mean ± standard deviation and conducted paired t-tests across cross-validation folds, which is a welcome improvement.

However, some concerns remain:

The manuscript does not clarify whether the assumptions of the paired t-test (e.g., normality) were verified.

Given the limited number of folds (n=5), the robustness of statistical testing may still be questioned.

The authors should provide additional justification for the choice of statistical test and, if possible, include complementary non-parametric testing or normality verification.

The authors clarify that the results of comparative models were directly cited from the literature rather than re-implemented under identical experimental conditions.

While this improves transparency, it raises concerns regarding fairness:

Differences in preprocessing, training protocols, and data splits may significantly affect performance.

Therefore, the comparison may not be strictly controlled.

The authors should more explicitly acknowledge this limitation and moderate claims of superiority. Ideally, re-implementation under a unified framework would strengthen the validity of comparisons, though this may be left as future work.

The authors have improved the clarity of variable definitions and provided a more structured explanation of the loss components.

However: the final mathematical formulation of the combined loss function is still not explicitly presented in a concise equation.

The relationship between the global Dice loss and the local boundary-restricted term would benefit from a clearer formal expression.

Include an explicit final loss equation and ensure all symbols are consistently defined.

The authors provide a more detailed explanation of using VASARI-based classification consistency as a proxy for segmentation quality.

This clarification is helpful. However: the argument remains somewhat overstated.

The claim that downstream consistency “directly proves” segmentation quality is too strong.

Rephrase this argument to reflect that downstream consistency provides supporting or indirect evidence, rather than definitive proof.

The authors have appropriately acknowledged the limitation regarding the lack of external validation and have moderated their claims.

Well, this is a strong improvement, and the revised discussion is now more balanced and scientifically appropriate.

Also, the addition of hardware specifications is appreciated.

However, important details are still missing: Model parameter size, Training time, Inference time

Include these details to ensure full reproducibility and to allow readers to assess computational feasibility.

The authors have clarified the misuse of the term “test set” and corrected the terminology throughout the manuscript.

The authors have made substantial improvements in response to the reviewer comments, particularly in terms of statistical analysis, transparency, and clarity.

However, several points still require minor but important revisions, particularly regarding:

Statistical rigor, Fairness of comparisons , Mathematical clarity, Reproducibility details

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Jun 22;21(6):e0351953. doi: 10.1371/journal.pone.0351953.r006

Author response to Decision Letter 3


20 Apr 2026

Response to Reviewers

Dear Editors and Reviewers,

We express our sincere gratitude to you and your colleagues for reviewing our submitted manuscript and providing valuable comments and suggestions. We highly appreciate these invaluable suggestions and believe they have played a crucial role in our research. We have carefully considered each of your suggestions, conducting thorough revisions to ensure the academic and methodological accuracy and credibility of our paper. Here, we sincerely respond to your review comments, hoping that our responses meet your expectations. Once again, we thank you for your valuable feedback and patience. Below are our responses to the specific comments:

1. Reviewer's Comment: “The authors have incorporated mean ± standard deviation and conducted paired t-tests across cross-validation folds, which is a welcome improvement. However, some concerns remain: The manuscript does not clarify whether the assumptions of the paired t-test (e.g., normality) were verified. Given the limited number of folds (n=5), the robustness of statistical testing may still be questioned.”

Response: We sincerely thank the reviewer for this insightful and constructive comment. We apologize for the lack of clarity regarding our statistical testing protocol and the rationale behind our cross-validation strategy. To address your concerns, we have clarified our methodology below and updated the manuscript accordingly.

1. We completely agree that strictly verifying the normality assumption is the best practice. Retrospectively, we conducted the Shapiro-Wilk test on the case-level differences. While most regions approximated normal distributions, a few exhibited slight skewness. To ensure absolute statistical rigor, we additionally performed the non-parametric Wilcoxon signed-rank test, which does not assume a normal distribution. The resulting p-values from the Wilcoxon test remain highly significant (p<0.01), perfectly consistent with the conclusions drawn from our original t-tests. We have updated the revised manuscript to explicitly describe this robust statistical procedure.

2. We deeply appreciate the reviewer’s concern regarding the number of folds. The choice of 5-fold cross-validation was a deliberate decision based on the bias-variance tradeoff. In our datasets (e.g., N=335 for BraTS 2019), increasing the number of folds (e.g., to 10-fold) would reduce the size of each validation set to only about 33 samples. Smaller validation sets are prone to high variance, meaning the performance metrics become overly sensitive to individual heterogeneous samples or noise, potentially leading to unreliable estimates of model generalization. A 5-fold CV ensures a more substantial validation set (n=67 per fold), providing a much more stable and representative estimate of the model. Furthermore, calculating 3D MRI configurations is computationally intensive; the 5-fold strategy optimally balances statistical stability and computational feasibility.

2. Reviewer's Comment: “The authors clarify that the results of comparative models were directly cited from the literature rather than re-implemented under identical experimental conditions. While this improves transparency, it raises concerns regarding fairness: Differences in preprocessing, training protocols, and data splits may significantly affect performance. Therefore, the comparison may not be strictly controlled. The authors should more explicitly acknowledge this limitation and moderate claims of superiority. Ideally, re-implementation under a unified framework would strengthen the validity of comparisons, though this may be left as future work.”

Response: We sincerely thank the reviewer for pointing out this critical caveat. We completely agree that comparing our results directly with those cited from the literature—without strictly controlling for preprocessing, exact cross-validation splits, and hardware/software environments—introduces potential biases and compromises the strict fairness of the comparison. we have made the following specific revisions to the manuscript:

1. We have significantly expanded the discussion in the “Comparative Experiments of GL-Net” section to explicitly warn readers that differences in data splits and pipelines may impact the performance metrics, and thus the comparisons should be interpreted as contextual benchmarks rather than strictly controlled head-to-head evaluations.

2. We have systematically reviewed the manuscript (especially the Abstract, Results, and Conclusion sections) and toned down definitive claims of “absolute superiority” (e.g., changing phrases like “outperforming several state-of-the-art algorithms” to “demonstrating highly competitive performance relative to reported benchmarks”).

3. As suggested, we have added a dedicated sentence in the “Conclusion” section stating that re-implementing these baseline models within a unified framework (e.g., standardized data splits and preprocessing pipelines) remains a crucial direction for our future work to establish more reliable comparisons.

3. Reviewer's Comment: “The authors have improved the clarity of variable definitions and provided a more structured explanation of the loss components. However: the final mathematical formulation of the combined loss function is still not explicitly presented in a concise equation. The relationship between the global Dice loss and the local boundary-restricted term would benefit from a clearer formal expression. Include an explicit final loss equation and ensure all symbols are consistently defined.”

Response: To address this issue, we have thoroughly revised the “Dynamic Weighted Loss Function for Edge Region Voxels” section. We have now decomposed the complex equation into three highly concise and explicit mathematical formulas:

1. The global Dice loss (L_Dice).

2. The boundary-restricted dynamic weighted cross-entropy loss (L_BRD).

3. The final combined loss equation expressed as a weighted sum (L_DiceBRD=L_Dice+λL_BRD), which explicitly illustrates the relationship between the global and local terms.

Furthermore, immediately following these equations, we have provided a unified, bulleted list to define every mathematical symbol (V,R,∣R∣,C,y_ic,p_ic,w_i,ε,λ) explicitly and consistently, leaving no room for ambiguity. We believe these modifications greatly enhance the mathematical readability and exactness of our proposed method. Please see the revised manuscript for these specific changes.

4. Reviewer's Comment: “The authors provide a more detailed explanation of using VASARI-based classification consistency as a proxy for segmentation quality. This clarification is helpful. However: the argument remains somewhat overstated. The claim that downstream consistency “directly proves” segmentation quality is too strong. Rephrase this argument to reflect that downstream consistency provides supporting or indirect evidence, rather than definitive proof.”

Response: We sincerely appreciate the reviewer’s careful reading and valid critique regarding the precision of our scientific claims. We completely agree that claiming downstream classification consistency “directly demonstrates” segmentation quality is overly absolute. While downstream task performance highlights the clinical utility of the generated masks, it is ultimately an indirect measure and should be properly framed as complementary evidence alongside geometric metrics like DSC and HD, rather than definitive proof of pixel-perfect segmentation. In accordance with your excellent suggestion, we have systematically reviewed the manuscript and meticulously toned down these claims, particularly in the “Abstract”, “VASARI-based Feature Analysis”, and “Conclusion” sections. We have rephrased the relevant sentences to explicitly state that downstream consistency “provides valuable complementary and indirect evidence” of the model’s reliability and clinical utility. We believe these revisions significantly enhance the scientific rigor and objectivity of our manuscript.

5. Reviewer's Comment: “The authors have appropriately acknowledged the limitation regarding the lack of external validation and have moderated their claims. Well, this is a strong improvement, and the revised discussion is now more balanced and scientifically appropriate. Also, the addition of hardware specifications is appreciated. However, important details are still missing: Model parameter size, Training time, Inference time. Include these details to ensure full reproducibility and to allow readers to assess computational feasibility.”

Response: We sincerely thank the reviewer for the highly encouraging feedback and for recognizing the improvements in our revised manuscript. We also appreciate you emphasizing the importance of computational details.

We apologize if these specific metrics were not prominent enough in our previous revision, which might have caused them to be overlooked. We are pleased to clarify that we have indeed included these exact details at the end of the “Experimental Setup and Preprocessing” section. To ensure absolute clarity, we summarize them here:

1. Model Parameter Size: The proposed GL-Net has a total parameter count of approximately 35.2 M;

2. Training Time: Under our hardware configuration (dual NVIDIA RTX 3090 Ti GPUs), the total training time for 100 epochs was approximately 14 hours.

3. Inference Time: During the testing phase, the average inference time per patient volume (a full 3D MRI scan) was strictly around 4.2 seconds (approx. 27 ms per slice).

We hope that these comprehensive revisions satisfactorily address all your concerns and that the revised manuscript is now deemed suitable for publication in your journal

Sincerely,

Huimin Lu

Attachment

Submitted filename: Response_to_Reviewers_auresp_3.docx

pone.0351953.s005.docx (23.5KB, docx)

Decision Letter 3

Taikyeong Jeong

4 May 2026

-->PONE-D-25-43663R3-->-->GL-Net: A Knowledge-Guided Gaussian-Gated and Layered Refinement Network for 3D MRI Segmentation of Brain Gliomas-->-->PLOS One

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

This paper presents a knowledge-based deep learning framework (GL-Net) for glioma segmentation through validation based on the BraTS dataset and VASARI. This study is methodologically valid, and the experimental design (including resection and statistical analysis) is suitable for publication in a journal. However, while suitable for publication, several points regarding interpretation and reporting must be modified.

(1) The claim of superiority over existing methods should be softened, as comparisons were not made in a strictly controlled environment. Please revise it to reflect competitive performance. The author is using very dangerous wording. "Comparison is not strictly controlled..." is incomprehensible to an experimenter.

(2) Clinical claims should be softened. In the absence of external validation, expressions such as "clinical utility" should be revised to indicate potential clinical relevance.

(3) p-values reported as "0.00" should be corrected to a standard format (e.g., p < 0.01)

==============================

Please submit your revised manuscript by Jun 18 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only   the individual author can complete the verification step; PLOS staff cannot   verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Taikyeong Ted Jeong, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments :

This paper presents a knowledge-based deep learning framework (GL-Net) for glioma segmentation through validation based on the BraTS dataset and VASARI. This study is methodologically valid, and the experimental design (including resection and statistical analysis) is suitable for publication in a journal. However, while suitable for publication, several points regarding interpretation and reporting must be modified.

(1) The claim of superiority over existing methods should be softened, as comparisons were not made in a strictly controlled environment. Please revise it to reflect competitive performance. The author is using very dangerous wording. "Comparison is not strictly controlled..." is incomprehensible to an experimenter.

(2) Clinical claims should be softened. In the absence of external validation, expressions such as "clinical utility" should be revised to indicate potential clinical relevance.

(3) p-values reported as "0.00" should be corrected to a standard format (e.g., p < 0.01).

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Jun 22;21(6):e0351953. doi: 10.1371/journal.pone.0351953.r008

Author response to Decision Letter 4


8 May 2026

Response to Reviewers

Dear Editors and Reviewers,

We express our sincere gratitude to you and your colleagues for reviewing our submitted manuscript and providing valuable comments and suggestions. We highly appreciate these invaluable suggestions and believe they have played a crucial role in our research. We have carefully considered each of your suggestions, conducting thorough revisions to ensure the academic and methodological accuracy and credibility of our paper. Here, we sincerely respond to your review comments, hoping that our responses meet your expectations. Once again, we thank you for your valuable feedback and patience. Below are our responses to the specific comments:

1. Reviewer's Comment: “The claim of superiority over existing methods should be softened, as comparisons were not made in a strictly controlled environment. Please revise it to reflect competitive performance. The author is using very dangerous wording. "Comparison is not strictly controlled..." is incomprehensible to an experimenter.”

Response: We sincerely thank the reviewer for this critical and highly constructive feedback. We completely agree that claiming absolute superiority is scientifically inappropriate when comparing our results with metrics directly cited from other publications, given the inevitable differences in data splits, preprocessing pipelines, and evaluation frameworks. We also deeply appreciate the reviewer pointing out the inappropriate and potentially misleading phrase "Comparison is not strictly controlled". To address this, we have thoroughly revised the manuscript. Specifically, we have:

1. Removed all variations of the phrase "not strictly controlled" and replaced them with standard academic terminology (e.g., "indirect comparison," "different evaluation frameworks").

2. Softened words like "superior," "outperforming," and "best" to "highly competitive," "comparable to state-of-the-art," and "demonstrates robust performance" throughout the Abstract, Results, and Conclusion sections.

3. 3. Clarified that our results show the model's strong potential and competitiveness, while explicitly acknowledging that a definitive head-to-head evaluation would require re-implementing all models within a unified framework (such as nnU-Net).

2. Reviewer's Comment: “Clinical claims should be softened. In the absence of external validation, expressions such as "clinical utility" should be revised to indicate potential clinical relevance.”

Response: We sincerely thank the reviewer for pointing this out. We fully agree that without validation on an independent, external clinical dataset, claiming "clinical utility" or "direct clinical applicability" is scientifically premature and overstates the current developmental stage of our model.

To ensure scientific rigor and adhere to standard reporting practices in medical image analysis, we have thoroughly reviewed the manuscript and softened all relevant clinical claims. Specifically, we have replaced terms such as "clinical utility" and "practical utility" with more objective and cautious expressions, including "potential clinical relevance," "translational potential," and "clinical potential." Furthermore, we have explicitly highlighted the critical need for future external validation on independent cohorts before any true clinical utility can be established. We believe these revisions accurately reflect the current limitations and the true scope of our work.

3. Reviewer's Comment: “p-values reported as "0.00" should be corrected to a standard format (e.g., p < 0.01).”

Response: We sincerely thank the reviewer for pointing out this formatting issue. We completely agree that reporting a p-value exactly as "0.00" is statistically inaccurate. Following your suggestion, we have carefully reviewed the entire manuscript, including all relevant texts and tables (Tables 3, 4, and 5). We have corrected all instances of "0.00" to the standard format "< 0.01". Accordingly, we have also updated the table footnotes to reflect these changes. We appreciate your rigorous attention to detail, which has helped us improve the statistical reporting standard of our paper.

We hope that these comprehensive revisions satisfactorily address all your concerns and that the revised manuscript is now deemed suitable for publication in your journal

Sincerely,

Huimin Lu

Attachment

Submitted filename: Response_to_Reviewers_auresp_4.docx

pone.0351953.s006.docx (19.9KB, docx)

Decision Letter 4

Taikyeong Jeong

3 Jun 2026

GL-Net: A Knowledge-Guided Gaussian-Gated and Layered Refinement Network for 3D MRI Segmentation of Brain Gliomas

PONE-D-25-43663R4

Dear Dr. Lu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Taikyeong Ted Jeong, Ph.D.

Academic Editor

PLOS One

Additional Editor Comments (optional):

As an academic editor, I appreciate the author's thoughtful response and hope for its publication in this journal.

Reviewers' comments:

Acceptance letter

Taikyeong Jeong

PONE-D-25-43663R4

PLOS One

Dear Dr. Lu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Taikyeong Ted Jeong

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0351953.s001.docx (20.1KB, docx)
    Attachment

    Submitted filename: Reveiwers suggestions for this essay.doc

    pone.0351953.s002.doc (24KB, doc)
    Attachment

    Submitted filename: Report_PONE-D-25-43663_R1_17.02.26 .pdf

    pone.0351953.s003.pdf (135KB, pdf)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pone.0351953.s004.docx (25KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_3.docx

    pone.0351953.s005.docx (23.5KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_4.docx

    pone.0351953.s006.docx (19.9KB, docx)

    Data Availability Statement

    The datasets used in this article are the brain tumor MRI datasets (BraTS2019 and BraTS2021) published by the Perelman School of Medicine at the University of Pennsylvania and can be found at: https://www.kaggle.com/datasets/debobratachakraborty/brats2019-dataset and https://www.kaggle.com/datasets/victorfernandezalbor/brats2021dataset.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES